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Studies in hereditary cancer syndromes have been crucial in the localization and 
identification of many cancer genes involved in both familial and sporadic cancers. 
Detection of genetic alterations in cancer susceptibility genes has provided implements for 
genetic testing and follow-up of individuals with increased cancer risk. Understanding of 
the molecular mechanism of tumorigenesis has provided tools for the development of 
better treatment and targeted drugs for cancer.  
In this study, a predisposing gene for a recently characterized cancer syndrome, hereditary 
leiomyomatosis and renal cell cancer (HLRCC), was identified and the role of the gene 
was investigated in other familial cancers and in no syndromic tumorigenesis. HLRCC is 
a dominantly inherited disorder predisposing predominantly to uterine and skin 
leiomyomas, and also to renal cell cancer and uterine leiomyosarcoma. The disease gene 
was recently localized in Finnish families to 1q42-q43 by a genome-wide linkage search. 
Independently in the UK, a clinically similar condition, multiple cutaneous and uterine 
leiomyomata (MCUL), was linked to the same chromosomal region, strongly suggesting 
that HLRCC and MCUL are actually a single syndrome. Linkage results were confirmed 
by detecting loss of heterozygosity (LOH) at the disease locus in most of the patients' 
tumors, suggesting that this predisposing gene actss a tumor suppressor. Through 
detailed investigation by genotyping of microsatellit  markers and haplotype construction 
in Finnish and UK HLRCC/MCUL families we were able to narrow the disease locus 
down to 1.6 Mb. Extensive mutation screening of know  and predicted transcripts in the 
target region resulted in identification of the HLRCC predisposing gene, fumarase 
(fumarate hydratase, FH). FH is a key enzyme in energy metabolism, catalyzing fumarate 
to malate in the tricarboxylic acid cycle (TCAC) in mitochondria. Germline alterations in 
FH segregating with the disease were detected in 25 of 42 HLRCC/MCUL families 
including whole-gene deletions, truncating small deletions/insertions and nonsense 
mutations, as well as substitutions or deletions of highly conserved amino acids. Biallelic 
inactivation was detected in almost all studied tumors of HLRCC patients. Furthermore, 
FH enzyme activity was reduced in the patients' normal tissues and was completely or 
virtually absent from tumors. Based on these findings, we extensively demonstrated that 
mutations in FH underlie the HLRCC/MCUL syndrome. In our studies of other familial 
cancers, evidence for involvement of FH defects was not found in familial prostate and 
breast cancers. 
To investigate the role of FH in sporadic tumorigenesis, we analyzed 652 lesions, 
including a series of 353 nonsyndromic counterparts of tumor types associated with 
HLRCC. Mutations in nonsyndromic tumors were rare and appeared to be limited to 
tumor types observed in the hereditary form of the disease. Biallelic inactivation of FH 
was detected in a uterine leiomyosarcoma, a cutaneous l iomyoma, a soft-tissue sarcoma, 
and in two uterine leiomyomas. In the uterine leiomy sarcoma and the cutaneous lesion 
FH mutations originated from the germline whereas the soft-tissue sarcoma harbored 
purely somatic changes. In uterine leiomyomas somatic mutations were detected in the 






inactivation is also involved in nonhereditary tumor development, and further support the 
hypothesis that FH acts as a tumor suppressor. The role of FH in predisposition to 
malignancies, renal cell carcinoma and leiomyosarcoma is important in the diagnosis and 
prevention of cancer among HLRCC patients. This study is of general clinical interest, 
because prior to our findings, little was known about the molecular genetics of uterine 
leiomyomas, the most common tumors of women. Discovery of FH and other TCAC 
defects in tumor predisposition adds to our knowledge of the contribution of basic 






REVIEW OF THE LITERATURE 
1. Genes and cancer 
Cancer is a genetic disease. A malignant tumor develops through accumulation of genetic 
changes in proliferating cells (Fearon and Vogelstein 1990). These changes include 
activation of oncogenes, dysfunction of stability genes (caretakers), or inactivation of 
tumor suppressor genes (Vogelstein and Kinzler 2004). Although multiple changes are 
required for malignant transformation, only a limited number of molecular pathways 
contribute to most cancers (Hahn and Weinberg 2002). 
The major knowledge of cancer genes is still based on rare, high penetrance alleles which 
have been identified using genetic linkage and positional cloning. Although the 
contribution of these genes in sporadic lesions has been extensively evaluated, the 
molecular events in common cancer have remained unclear. 
1.2. Oncogenes 
Oncogenes are excessively activated counterparts of protooncogenes, which are involved 
in normal cellular signaling. In cancer, protooncogenes are activated through 
chromosomal amplification, rearrangements, or activting point mutations, leading to 
excessive cell proliferation or aberrant differentiation (Bishop 1991).  
Most of oncogene alterations occur at the somatic level and are common in many tumor 
types (Tumor Gene Database, http://condor.bcm.tmc.edu/oncogene.html). RAS genes are 
the most frequently mutated oncogenes in human cancer cells (Giehl 2005). Aberrant 
activation of RAS proteins is involved in practically all processes of malignant 
transformation, such as gene expression, cell cycle progression, apoptosis, exocytosis, 
aberrant angiogenesis, tissue invasion, and metastasis (Symons and Takai 2001, Campbell 
and Der 2004). RAS proteins are members of a large sup rfamily of over 100 small GTP-
binding proteins, commonly classified into six subfamilies (Takai et al. 2001). In human 
tumors, the majority of RAS mutations occur in the Kirsten type Harvey sarcoma virus 
homolog (K-RAS) gene (Giehl 2005). Mutational K-RAS activation is involved in most of 
pancreatic adenocarcinomas and in third of lung and colorectal cancers (Almoguera et al. 
1988, Rodenhuis et al. 1988, Bos et al. 1987).  
Inherited oncogene mutations are rare compared to somatic alterations. Rearranged during 
transfection protooncogene (RET), v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog (KIT), met protooncogene (MET), and cyclin-dependent kinase 4 
(CDK4) are probably the only known high-penetrance oncogenes mutated in familial 
cancers. Multiple endocrine neoplasia type II (MEN2) is characterized by medullary 
thyroid carcinoma and pheochromocytoma (Schimke and Hartmann 1965). A 






in the RET protooncogene of MEN2 families (Mulligan et al. 1993, Quadro et al. 2001). 
Mutations in the KIT gene can be found either somatically or in the germline, underlying 
gastrointestinal stromal tumor predisposition (Hirota et al. 1998, Nishida et al. 1998). 
MET mutations were first found in the germline of affected members of hereditary 
papillary renal cell carcinoma (HPRC) families, and subsequently also in sporadic cases 
(see section 3.2.3) (Schmidt e al. 1997). CDK4 is included in protein complexes 
controlling passage through the G1 checkpoint of the cell cycle (Sherr 1993). Germline 
mutations in CDK4 have been detected, though very rarely, in familial malignant 
melanoma (FMM) (Zuo et al. 1996).  
1.3. Stability genes 
Stability genes, also referred to as caretakers, promote tumorigenesis in a totally different 
way than do oncogenes and tumor suppressors. Stability genes keep genetic alterations at a 
minimal level, and when inactivated mutations in other genes occur at higher levels, 
whereas tumor suppressors and oncogenes accelerate neoplastic growth by increasing 
tumor cell number through stimulation of cell proliferation or the inhibition of apoptosis 
or cell-cycle arrest (Friedberg 2003, Vogelstein and Kinzler 2004). Although potentially 
all genes are targets of increased genomic instability, only somatic mutations in 
oncogenes, tumor suppressor genes, or other stability genes are critical for tumor 
development (Akiyama et al. 1997). 
Stability genes include mismatch repair (MMR), nucleotide-excision repair (NER), and 
base-excision repair (BER) genes responsible for repai ing normal DNA replication errors 
(Friedberg 2003). Failures in these systems can lead to ccumulation of somatic mutations 
in cells and, accordingly, increased predisposition t  severe conditions. Germline 
mutations in the MMR genes, MLH1, MSH2, PMS2, and MSH6 have been found to 
predispose to HNPCC (Fishel t al. 1993, Leach et al. 1993, Bronner et al. 1994, 
Papadopoulos et al. 1994). Because simple repetitive sequences are particul ly prone to 
replication errors, microsatellite instability (MSI) can be used as a landmark in HNPCC 
(Ionov et al. 1993). Other stability genes control chromosomal st bility, through such 
processes as mitotic recombination and chromosomal segregation. Mutations in, for 
example, BRCA1 and BRCA2 predispose to familial breast cancer (Miki et al. 1994, 
Wooster et al. 1995). 
1.4. Tumor suppressor genes and loss of heterozygos ity (LOH)  
Most hereditary cancer syndromes are caused by mutations in tumor suppressor genes. 
These genes are needed to keep cells under control (Marshall 1991). Compared to sporadic 
cases, patients with germline mutations have a higher risk of developing secondary 






typically involved in the transduction of extra cellular signals, regulation of transcription, 
or controlling the cell cycle (Smith et al. 1998).  
Several tumor suppressor genes predisposing to hereditary cancer syndromes have been 
shown to be a key element also in nonsyndromic cancers (Bishop 1991, Soussi et al. 
2005). Many of these genes have been found to be mutated and involved in cancer 
progression at a somatic level. Tumor protein TP53 is one of the best examples of these 
functions. The TP53 gene is inactivated in approximately 50% of human c cers, in most 
cases only in somatic cells (Harris 1996, Soussi et al. 2005, Soussi and Lozano 2005). 
Germline mutations in TP53 predispose to Li-Fraumeni syndrome, but have also been 
reported in many sporadic cancers (Malkin et al. 1990, Camplejohn and Rutherford 2001).  
The main evidence for the presence of tumor suppresso  genes was provided by a study by 
Knudson (1971), where he suggested that two events were required for retinoblastoma 
development. In hereditary cases, one mutation has occurred in the germline and is 
inherited. The second mutation has taken place at the somatic level and is typically a 
deletion of a larger chromosomal region containing the respective gene. Such 
chromosomal events result in homozygosity of the region, i.e. loss of heterozygosity 
(LOH) (Figure 1). These two genetic events in the Knudson’s model were afterwards 
shown to represent biallelic inactivation of a tumor suppressor gene, human 










Figure 1. Loss of heterozygosity (LOH) in hereditary and sporadic cancer. Typically, two events 
are needed to inactive a tumor suppressor gene. In hereditary cancers, the first mutation is 
inherited in all cells. In a tumor cell of the target tissue a loss of a wild type allele through 
deletion of the chromosomal material leads to inactivation of a possible tumor suppressor gene. 
The s hit can also be a point mutation in another allele. In sporadic cancers, both events take 
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Inactivation of VHL, the second example of classical tumor suppressor genes, has been 
shown to predispose to von Hippel-Lindau syndrome (VHL, OMIM 193300) (Latif et al. 
1993, Crossey et al. 1994). VHL is a dominantly inherited familial cancer syndrome 
predisposing to a variety of malignant and benign neoplasms, most frequently renal cell, 
retinal, and spinal hemangioblastoma carcinoma, pheochromocytoma, and pancreatic 
tumors (see section 3.2.1.) (Neumann and Wiestler 1991).  
 
2. Uterine leiomyomas 
Uterine leiomyomas (fibroids) are the most common tumors in women, being present in at 
least 25% of women (Buttram 1986). Most myomas are symptomless leading to possible 
underestimation of the prevalence. Careful pathological examination with new imaging 
techniques suggests that the prevalence is as high as 77% (Cramer and Patel 1990). 
Despite their benign nature, uterine fibroids are a significant health issue. Although most 
myomas are symptomless, many women suffer from abdominal pain, abnormal bleeding, 
and reproductive dysfunction (Stewart 2001). Uterin myomata is the leading cause for 
hysterectomy in many countries. 
 Myomas arise from the smooth muscle cells of the uterus. The pathophysiology of 
myomas is not well understood. It is known that myoas follow life-cycle changes of the 
reproductive hormones estrogen and progesterone (Rein 2000). It has been proposed that 
risk factors associated with uterine leiomyomas, such as early menarche, obesity, diet, and 
smoking act by regulating these hormones (Flake et al. 2003). The most common pathway 
to myoma development includes the transformation of normal myocytes into abnormal 
ones (Cramer and Patel 1990). Mosaicism is a frequent finding in uterine leiomyomas 
with chromosomal rearrangements (Xing et al. 1997, Gross et al. 2004).  
Little is known about the molecular background of these lesions. Mutation analyses of 
candidate genes such as TP53, P53-binding protein gene (MDM2), K-RAS, and CCAAT 
displacement protein (CDP) have been negative ((Hall et al. 1997, Patrikis et al. 2003). 
Other than activating K-RAS mutations reported in one study, no specific point mu ations 
underlying nonsyndromic leiomyomas have been identifi d. However, the contribution of 
chromosomal rearrangements to the development of these lesions has long been evident 
(Pandis et al. 1991, Hall et al. 1997).  
Nonrandom chromosomal abnormalities have been observed in 40 to 50% of surgically 
removed uterine leiomyomas (Flake et al. 2003). The most common cytogenetic changes 
are translocations between chromosomes 12 and 14 (20%), deletions and translocations in 
chromosome 7q (17%), trisomy of chromosome 12, and a wide variety of aberrations of 
6p21 (< 5%) (Meloni et al. 1992, Ozisik et al. 1993, Sargent et al. 1994, Ishwad et al. 
1995, Sornberger et al. 1999, Ligon and Morton 2000). Cytogenetic abnormalities similar 
to fibroids have also been observed in other mesenchymal tumors, such as lipomas and 






chromosomes 12 and 14 typically include the translocati n t(12;14)(q15;q23-q24), 
involving a chromosomal segment of a gene encoding a member of the high mobility 
group proteins, HMGA2 (Pandis et al. 1990, Mine et al. 2001). Altered gene expression, 
the aberrant splicing of HMGA2, or cytogenetic translocation leading to chimeric fusion of 
HMGA2 and a target gene are frequent events in uterine le omyomas (Tallini and Dal Cin 
1999). HMGA2 and the DNA repair gene RAD51L1 have been hypothesized to create 
pathologically significant fusion transcripts (Takahas i et al. 2001). Although HMGA2-
RAD51L1 fusion transcripts or their incorrectly spliced products have been detected, the 
pattern of rearrangements suggests that dysregulated expression of HMGA2, not the 
formation of fusion transcripts, is the principle mechanism in the development of uterine 
leiomyomas (Quade t al. 2003). Elevated expression of the igh mobility group AT-hook 
1 (HMGA1) gene has also been observed in uterine leiomyomas. The dysregulating 
mechanism may be similar to HMGA2 including post-translational modifications or 
cytogenetic rearrangements at the HMGA1 locus on 6p21 (Sornberger t al. 1999). 
Consistent with cytogenetic studies, molecular genetic analyses have confirmed the loss of 
genetic material on 7q21-q32, suggesting the localization of a tumor suppressor gene 
important for myoma development in this region (Ishwad et al. 1997, Mao et al. 1999). In 
a genome wide allelotyping effort, LOH was observed on 7q22-q23 (9%), 1q42-q42 (2%), 
and 16q12-q22 (2%) (Mao et al. 1999). Although the minimal commonly deleted region 
on 7q22 has been recently reduced to 2.3 Mb, no causative gene to uterine leiomyoma 
predisposition has been successfully identified in th s region (Vanharanta et al. 2005).  
The animal model for human tuberous sclerosis, the Eker rat, shows additional evidence 
that HMGA2 plays a key role in human uterine leiomyata (Everitt et al. 1995). In the 
majority of Eker rat myomas HMGA2 protein is expressed, while in the normal 
myometrium HMGA2 is completely lost (Hunter t al. 2002). Eker rats are heterozygous 
for mutations in the tuberous sclerosis complex-2 (TSC2) tumor suppressor gene, 
segregating uterine leiomyomas and leiomyosarcomas, renal cell carcinomas (RCC), and 
hemangiosarcomas of the spleen (see section 3.2.4.) (Hino et al. 1999, Cook and Walker 
2004).  
Genome wide gene expression studies provide new clues to pathways contributing to the 
pathogenesis of uterine leiomyomas. A comparative analysis of nine gene expression 
studies revealed common genes aberrantly expressed in myomas (Arslan et al. 2005). 
Under-expression of alcohol dehydrogenase 1A (ADH1) and aldehyde dehydrogenase 1 
(ALDH1) in uterine leiomyoma compared to normal myometrium could potentially link 
HMGA1/2 related chromosomal aberrations to the exprssion data. The HMG protein 
competitively binds to the ADH class I HNF-1/HMG1 promoter, affecting ADH1 gene 
transcription (Edenberg 2000). Arslan et al. (2005) concluded that there is a co-
requirement of increased estrogens and retinoid acithat promote tumor growth. Up-
regulation of insulin growth factor 2 (IGF2) and down-regulation of IGF binding proteins 
(IGFBP) have been the most regular observation in myoma expression studies. IGF2 is 
known to be involved in cell proliferation and differentiation. Furthermore, extra cellular 
matrix formation through transforming growth factor beta (TGFB) and dermatopontin 






2.1. Genetic predisposition to leiomyomas 
The hereditary form of uterine leiomyoma is normally discussed in the context of multiple 
cutaneous and uterine leiomyomatosis syndrome (MCUL). The first report on the 
hereditary form of cutaneous leiomyomatosis was based on an Italian family with three 
affected half first cousins. (Kloepfer et al. 1958). A cutaneous leiomyoma family with 
uterine myomata was described by Mezzadra in 1965 (Mezzadra 1965). Autosomal 
dominant inheritance with decreased penetrance was supported by these pedigrees. The 
inherited disorder, characterized by the appearance of uterine leiomyoma and/or multiple 
cutaneous leiomyoma, was called Reed’s syndrome (Red et al. 1973). Other family 
studies have further defined the role of the hereditable component in myomata. A study of 
97 leiomyomata families showed that the prevalence of uterine fibroids is 2.2-fold higher 
in families with two or more affected individuals than in controls (Vikhlyaeva et al. 1995). 
Furthermore, in twin-pair studies, the hysterectomy rate in monozygotic twins was 2-fold 
higher than in dizygotic twins (Treloar et al. 1992). An average estimate of familial risk in 
the first degree relatives of affected probands is approximately 25%, and heritability 
according to recurrence rate in siblings is 0.26-0.80 (Kurbanova et al. 1989a, Kurbanova 
et al. 1989b, Snieder et al. 1998, Luoto et al. 2000). These findings of a significant genetic 
factor in uterine myomata predisposition are compatible with the observation of 2-3-fold 
higher incidence of fibroids in African-American than in Caucasian women (Kjerulff et al. 
1993, Marshall et al. 1997). Clinical and molecular features in familial uterine myomas 
are different from their sporadic counterparts (Okolo et al. 2005). Significantly higher 
incidence of abdominal swelling, dysmenorrhoea, dyspareunia, and early onset of disease 
in cases with family history of fibroids compared to those without have been reported. 
Additionally, patients with a family history of leiomyomas more often have various 
cancers, mainly in breast, stomach, and oesophagus (Okolo et al. 2005). 
 
3. Renal cell cancer (RCC) 
Kidney cancer accounts for approximately 2% of all c ncer cases worldwide (McLaughlin 
and Lipworth 2000). Benign papillary adenomas are th  most common lesions of the 
kidney (Van Poppel et al. 2000). Renal oncocytoma comprises about 3 to 5% of renal 
neoplasms in surgical series (Kovacs et al. 1997). The third subclass of benign neoplasms 
includes metaphoric adenomas and adenofibromas. The malignant tumors are almost 
exclusively renal cell carcinomas originating from the epithelium or collecting tubules of 
the kidney. Based on morphological features, RCC can be divided into clear cell 
(conventional, non-papillary), papillary (chromophil), chromophobe, collecting duct, and 
unclassified subtypes (Kovacs et al. 1997, Storkel et al. 1997). 
Clear cell carcinoma accounts for 70% of malignant re al neoplasms (Storkel t al. 1997). 






cytoplasm. The growth pattern may be solid, trebecular, tubular, or cystic with a 
characteristic highly branching vascularity pattern (Reuter and Presti 2000).  
Papillary renal carcinoma is the second most common alignancy of the renal tubular 
epithelium and accounts for approximately 10% of cases (Kovacs et al. 1997). Papillary 
RCC is typically divided into two morphologically distinct subgroups (Delahunt and Eble 
1997). Papillary type I tumors consist of papillae and tubular structures covered by small 
cells with pale cytoplasm and characterized by small oval nuclei with inconspicuous 
nucleoli, frequent glomeruloid papillae, and foamy acrophages in papillary cores. Type 2 
tumors consist of papillae covered by large cells with voluminous eosinophilic cytoplasm 
and characterized by pseudostratified and large nuclei with prominent nucleoli, 
glomeruloid papillae, and edematous papillae. Type 2 tumors are larger and occur more 
commonly at younger ages than type I tumors (Delahunt and Eble 1997). 
3.1. Familial renal cell cancer (RCC) syndromes 
3.1.1. von Hippel-Lindau disease (VHL) 
Clear cell carcinomas, pheochromocytomas, retinal hemangioblastomas, and central 
nervous system tumors are typical tumors in von Hippel-Lindau disease (VHL) (Maher t 
al. 1990). Familial aggregation of retinal angiomas and central nervous system 
hemangiolipomas was reported by Hippel and Lindau in the beginning of the 20th century 
(Table 1) (von Hippel 1904, Lindau 1927).  
The VHL gene was mapped by linkage analysis to chromosome 3p25 in 1988 and 
identified five years later (Seizinger t al. 1988, Latif et al. 1993). A chromosomal loss on 
3p was first found in sporadic renal cell carcinomas and subsequently in hereditary cases 
suggesting that one or more tumor suppressor genes r levant in RCC could be located in 
this region (Zbar et al. 1987, Tory et al. 1989, Kovacs et al. 1991).  
In later reports, it has been shown that tumor or cyst development in VHL syndrome is 
linked to somatic inactivation, through a point mutation or hypermethylation of the 
promoter region, or loss of the remaining wild type all le of the VHL gene (Crossey et al. 
1994, Herman et al. 1994, Shuin et al. 1994, Chen et al. 1995, Prowse et al. 1997). VHL 
consists of three exons and is widely expressed in both fetal and adult tissues (Iliopoulos 
et al. 1995, Richards et al. 1996).  
More than 300 different VHL mutations have been included in the Human Gene Mutation 
Database so far. The large amount of mutation data hs made reasonable genotype-
phenotype comparisons possible (Stenson et al. 2003). In VHL patients approximately 20 
to 30% of VHL mutations are whole or partial gene deletions, and 23 to 27% are nonsense 







Table 1. Most common familial cancer syndromes associated with renal cell cancer (RCC). 









C lear cell carcinoma 
Pheochromocytoma 
Retinal hemangio lipoma 






























RCC (mostly clear cell) 
Skin lesions 
Central nervous system tumors 
Mental disorders 














Benign skin tumors 
Pneumothorax, lung cysts 
RCC (mostly 
chromophobe/oncocytic) 
Rat (Nihon rat): 
RCC 

















Uterine and/or skin leiomyomas 
RCC (mostly papillary type 2) 
Uterine leiomyosarcoma 
No animal models 
  
These mutations are characteristic for subtype 1 VHL with high risk of renal cell 
carcinoma and absence of pheochromocytoma, whereas families at high risk of developing 
pheochromocytoma (type 2) harbor almost exclusively VHL missense mutations (Zbar et 
al. 1996, Chen et al. 1996, Maher et al. 1996).  
Biallelic VHL inactivation is common in both sporadic hemangioblastomas and sporadic 
clear cell renal carcinomas. VHL is somatically mutated in approximately 33 to 57%, and 
hypermethylated in up to 20% of sporadic RCCs, and is restricted to the clear cell subtype 
of tumors (Foster et al. 1994, Gnarra et al. 1994, Herman et al. 1994, Shuin et al. 1994, 
Whaley et al. 1994) Similarly, VHL mutations have been detected in 30 to 50% of 
sporadic hemangioblastomas, but rarely in sporadic pheochromocytomas (Hofstra et al. 
1996, Bender et al. 2000, Dannenberg et al. 2003). Studies examining a variety of other 
sporadic tumors have shown that somatic VHL mutations are rare in tumor types that are 






The VHL protein is part of an ubiquitin ligase complex that degrades hypoxia-inducible 
factor 1 alpha (HIF1α) in the presence of oxygen. In low oxygen conditions r when VHL 
is mutated, stabilization of HIF1α leads to angiogenesis, increased proliferation and
decreased apoptosis (Carmeliet et al. 1998, Maxwell et al. 1999). Angiogenesis, in many 
cases particularly through HIF1α regulation, has been suggested to be involved directly or 
indirectly in most oncogenic or tumor suppressor pathw ys (Vogelstein and Kinzler 
2004). In mice, targeted inactivation of Vhl has been shown to cause accelerated 
angiogenesis in many organs and vascular tumors in liver (Table 1) (Haase t al. 2001, Ma 
et al. 2003).  
3.1.2. Chromosome 3 translocations  
In a subset of families the occurrence of RCCs co-segregates with the presence of 
constitutional chromosome 3 translocations. Such phenomena can be employed to identify 
novel candidate genes at or near the translocation break-points for hereditary RCC and 
other cancers. Although co-occurrence of somatic VHL mutations with balanced 
translocations has been reported in the majority of cases, not all the familial RCCs have 
been shown to carry a VHL change (Bonne t al. 2004).  
A family with 10 RCC cases with a chromosome 3 balanced translocation was published 
by Cohen et al. in 1979 (Cohen et al. 1979). This cytogenetic rearrangement 
t(3;8)(p14;q24) produced a fusion of fragile histidine triad (FHIT) and translocation in 
renal carcinoma on chromosome 8 (TRC8) genes (Ohta et al. 1996, Gemmill et al. 1998). 
Interestingly, in Drosophila TRC8 was shown to directly interact with VHL and inhibit 
growth when over-expressed (Gemmill et al. 2002). However, evidence that FHIT is 
causally related to renal or other malignancies has remained controversial (Gemmill et al. 
1998). 
Two other break-point spanning genes, disrupted in renal carcinoma 2 and 3 (DIRC2 and 
DIRC3) have been localized based on a constitutional translocation t(2;3)(q35;q21) 
resulting in the formation of a DIRC3-HSPBAP1 fusion transcript (Bodmer et al. 2002, 
Bodmer et al. 2003). Heat-shock 27-kd protein-associated protein 1 (HSPBAP1) has been 
found to interact with HSP27, one of the small heat shock proteins, which are suggested to 
play essential role in stress responses and cancer (Bodmer et al. 2003, Mosser and 
Morimoto 2004). Interestingly, both of these fusion products are transcribed from the 
derivative chromosome that is lost during tumor development (Gemmill et al. 1998, 
Bodmer et al. 2003).  
In addition to FHIT and HSPAP1, some other translocation-associated genes, such as 
LSAMP coding limbic system-associated membrane protein and NORE1 coding RAS 
associated domain family protein 5, have been proposed to play a role in cellular stress 
signaling and thereby probably increase the susceptibility to somatic loss of the 
translocation derivative 3 chromosomes (Chen t al. 2003). At present, many 







Multiple evidence, including familial and non-familial cases, has shown that chromosome 
3 translocations are a risk factor for RCC (Kovacs et al. 1989, Schmidt et al. 1995, 
Bodmer et al. 1998, Gemmill et al. 1998, Koolen et al. 1998, Kanayama et al. 2001, 
Bodmer et al. 2002, Melendez et al. 2003, Van Erp et al. 2003, Rodriguez-Perales et al. 
2004). In conjunction with allele segregation analysis, frequent loss of derivative 
chromosome 3 has been detected. In addition, novel inactivating mutations, including 
different mutations from the same patient’s tumors, have been found in VHL so far 
(Schmidt et al. 1995, Bodmer et al. 1998, Kanayama et al. 2001). Based on these findings, 
a three-step model of RCC development has been proposed: 1) non-homologous 
chromatid exchange resulting in balanced chromosome 3 translocation, 2) loss of 
derivative chromosome 3 containing the p arm segment, and 3) somatic mutations in VHL 
or potentially also in other genes in the region (Bodmer et al. 2002a, Bodmer et al. 2002b, 
Pavlovich and Schmidt 2004). However, novel combinatori l molecular and cytogenetic 
analyses reveal complex genetic alterations in non-papillary RCC (Strefford et al. 2005). 
3.1.3. Hereditary papillary renal carcinoma (HRPC)  
Hereditary papillary renal carcinoma (HPRC) is a rare dominantly inherited cancer 
syndrome with reduced penetrance (Zbar et al. 1995). Malignant papillary renal 
carcinomas were first characterized by trisomy of chromosomes 7, 16, or 17 and, in men, 
by loss of the Y chromosome (Kovacs 1993). Later, the predisposing gene was mapped to 
7q31-q34, and germline mutations in a tyrosine kinase domain of MET protooncogene 
were identified in affected members of HPRC families and in a subset of sporadic 
papillary renal carcinomas (Table 1) (Schmidt et al. 1997). Overexpression and 
duplication of the MET oncogene was suggested to be crucial step in the pathogenic 
pathway of papillary renal tumors (Fischer t al. 1998). MET mutants also exhibited 
increased levels of tyrosine phosphorylation and enhanced kinase activity when compared 
with wild-type MET (Jeffers et al. 1997). Invasive and metastatic properties of MET 
mutants were demonstrated as well in cell lines as in mice (Giordano et al. 1997, Jeffers et 
al. 1998). In transgenic mice, activated Met induces predominantly metastatic mammary 
adenocarcinoma (Liang et al. 1996, Jeffers et al. 1998).   
The MET protooncogene encodes a transmembrane tyrosine kinase receptor for a 
hepatocyte growth factor, and drives a cellular program known as invasive growth. 
Aberrant invasive growth is known to be associated with invasion, metastasis, and 
neoplastic transformation of cells (Park et al. 1987, Bottaro et al. 1991, Comoglio and 
Trusolino 2002). The oncogenic potential of MET, especially through overexpression of 
the protein, has been reported in numerous human cancers (Di Renzo et al. 1991, Natali et 
al. 1996). The overexpression of the MET receptor in hypoxia is probably activated by 
hypoxia inducible transcription factors HIF1α and AP-1. Recently, molecular genetic 
evidence linking MET oncogenic activity and homeostasi  has been reported (Boccaccio 






3.1.4. Tuberous sclerosis complex (TSC) 
Tuberous sclerosis complex (TSC) is an autosomal dominant multi-system disorder with 
characterized by seizures, mental retardation, autism, epilepsy, and tumors in the brain, 
retina, heart, kidney, and skin (Table 1) (Roach et al. 1998). In adults, complications 
arising from renal, lung, heart, and brain pathology are the most significant cause of death 
(Shepherd et al. 1991). Epithelial renal manifestations of TSC include polycystic disease, 
oncocytomas, and RCC (Bjornsson et al. 1996, Henske 2005). Angiolipomas originate 
from mesenchymal cells, and are the most common renal lesion in TSC. Most 
angiolipomas are benign, although they are responsible for the most severe clinical 
symptoms because of their abnormal vascularity which can lead to spontaneous life-
threatening bleeding (Iliopoulos and Eng 2000). A specific feature in TSC, different from 
for example VHL and MET related renal carcinomas, is the substantial heterogeneity in 
renal manifestations, including clear cell, papillary, and chromophobe carcinomas 
(Bjornsson et al. 1996, Al-Saleem et al. 1998).  
The majority of TCS patients exhibit cutaneous signs or lesions (Webb et al. 1996, Sun et 
al. 2005). Although 80% of the most prevalent skin lesion , hypomelanotic macules and 
forehead fibrous plaques are non-sympomatic, they ar  important in the early diagnosis of 
the disease. The rest of the skin manifestations are symptomatic and need clinical 
treatment (Webb et al. 1996). 
Two genetic loci of TSC have been identified: TSC1, which maps to 9q34, and TSC2, 
which maps to 16p13.3 (Consortium 1993, van Slegtenhorst et al. 1997). Large mutation 
analysis studies have addressed the differences between phenotypes in TSC1 and TSC2 
(Jones et al. 1999). Mutations of TSC2 occur more frequently and their clinical symptoms 
in central nervous system and renal manifestations are more severe than of those TSC1. 
The TSC genes undergo LOH in the majority of lesions, strongly suggesting their role as 
tumor suppressors (Green t al. 1994a, Green et al. 1994b).  
The Eker rat is the first autosomal dominant inherited rodent model for RCC (Eker et al. 
1981). In addition to renal manifestations, Eker rats lso develop leiomyomas and 
leiomyosarcomas of the uterus, mostly from smooth muscle of the cervix (Everitt et al. 
1995). The predisposing defect underlying this phenotype was shown to be a mutation in 
the Tsc2 tumor suppressor gene, which was inactivated by a large inherited deletion and 
LOH in the Tsc2 locus (Yeung et al. 1994, Kobayashi et al. 1995).  
In contrast to human TCS patients, Eker rats develop multifocal, bilateral RCC with 100% 
incidence (Table 1) (Everitt et al. 1992). Although these tumors differ from the clear cell 
type renal lesions frequently observed in human TSC, they share many similarities, like 
tubular cell origin and high level of vascularization, with their human counterparts.  
Eker rat leiomyomas are histologically similar to their human counterparts, and occur at 
the high frequency of over 60% in females (Everitt et al. 1995). Eker leiomyomas have 
been shown to exhibit a 50% incidence of loss of the wild-type Tsc2 allele and an almost 
uniform loss of tuberin protein expression, implicating loss of function of the Tsc2 gene in 






important role in the development of leiomyomas of Eker rats. Eker leiomyomas and cell 
lines derived from them express both estrogen and progesterone receptors and respond to 
estrogen stimulation (Howe et al. 1995a, Howe et al. 1995b). 
Conventional Tsc1 and Tsc2 knock-out mice have also been generated to further 
understand the molecular mechanisms of TSC (Kobayashi et al. 1999, Onda et al. 1999, 
Kobayashi et al. 2001). Heterozygous mice developed renal and liver tumors whereas 
homozygous animals died during the embryonic stage. Th  finding that Tsc2 heterozygous 
mice develop renal tumors at younger age than Tsc1 animals is concordant with the 
observations that patients with TSC2 mutations have more severe disease compared to 
TSC1 mutation carriers (Dabora et al. 2001). 
Genetic and biochemical analyses have pointed out that the proteins hamartin and tuberin, 
the products of the TSC1 and TSC2 genes, respectively, form a heterodimer in intact cells 
(van Slegtenhorst et al. 1998). Pathological mutations in TSC disrupt this interaction, 
demonstrating that hamartin and tuberin act as a complex in tumor suppression (Hodges et 
al. 2001). Genetic studies in mammalian systems and Drosophila have shown that the 
hamartin/tuberin complex functions in inhibition of cell growth and cellular proliferation 
by downregulating the mTOR (mammalian target for rapamycin) signaling network (Hino 
et al. 2001, Potter et al. 2001, Tapon et al. 2001, Kwiatkowski 2003). mTOR controls a 
large and diverge set of growth-related signaling pathways, including activation of 
translation initiation in response to amino acids (i.e. nutrients) and growth factors, actin 
cytoskeleton organization, membrane traffic and protein degradation, protein kinace C 
signaling, ribosome biogenesis, and transcription (reviewed by Schmelzle and Hall 2000).    
3.1.5. Birt-Hogg-Dudé syndrome (BHD) 
Birt-Hogg-Dudé syndrome (BHD) is an autosomal dominant disease characterized by 
benign skin tumors, hair follicle hamartomas, and is associated with the development of 
pneumothorax, lung cysts, and renal tumors (Table 1) (Birt et al. 1977, Toro et al. 1999, 
Schmidt et al. 2001). A spectrum of different types of renal tumors are detected in BHD 
patients including chromophobe, oncocytoma, clear cell, and papillary type lesions, the 
most prevalent being chromophobe/ oncocytoma hybrid (Pavlovich et al. 2002). Renal 
manifestations are usually bilateral and have been shown to arise in 15-30% of BHD 
patients. Protein-truncating mutations were recently found in a novel gene called folliculin 
(FLCN) encoding a highly conserved protein with a frequency of 44% in BHD families 
(Nickerson et al. 2002).  
While no uterine leiomyomas have been reported in human BHD patients, a canine model 
for BHD develops skin lesions, uterine leiomyoma, and RCC histologically similar to 
human BHD (Moe and Lium 1997). A disease locus was m pped to a small region on 
canine chromosome 5, and associated mutations were lat  found in the homologue of the 
human BHD gene (Jonasdottir et al. 2000, Lingaas et al. 2003).  
Moreover, the Nihon rat, a rodent model for BHD, displays a dominantly inherited 






histology (Okimoto et al. 2000). Nihon rat RCC susceptibility is associated with a 
truncating insertion in the rat BHD gene, and LOH of the wild type allele in tumors 
(Okimoto et al. 2004). 
3.1.6. Hereditary leiomyomatosis and renal cell can cer (HLRCC)  
The association of cutaneous leiomyomas, uterine leiomyosarcoma, and metastasized 
renal cell cancer was described for the first time in 1973, although no cancer syndrome 
behind it was proposed (Reed t al. 1973). The HLRCC syndrome was described in 2001 
(Launonen et al. 2001). The tumor predisposition in HLRCC was suggested to be 
dominantly inherited including susceptibility to cutaneous and uterine leiomyomas with 
high penetrance, and leiomyosarcoma and renal cell cancer with reduced penetrance 
(Table 1).  Three reported Finnish HLRCC families included 26 affected individuals 
(Kiuru et al. 2001, Launonen et al. 2001). All except one male exhibited skin lesions 
(83%), cutaneous nodules or leiomyomas, and 14 out of 20 (70%) females were diagnosed 
with uterine leiomyomas. In addition to typical lesions, four patients have been reported to 
have leiomyomas with atypia (Kiuru et al. 2001, Launonen et al. 2001). Two cases with 
uterine leiomyosarcoma were identified; one of them had also been diagnosed with breast 
cancer. The most common malignant lesion was renal cell cancer, which was diagnosed in 
seven (27%) HLRCC family members at a relatively young age (33 to 48 years).  
To prove that HLRCC was a new cancer syndrome, Launone  et al. (2001) excluded the 
possibility of already known cancer genes as the cause of the disease. VHL and tuberous 
TSC were excluded because of the lack of characteristic enal and extra-renal features in 
HLRCC. Especially crucial was the morphological picture of the renal cancers in HLRCC 
because it was unique, displaying rare clear cell type 2 histology (Kiuru et al. 2001, 
Launonen et al. 2001). In type 2 renal cell carcinoma cytoplasm is abundant, nuclei are 
large, and very large inclusion-like nucleoli can be seen. In contrast to HLRCC, papillary 
renal carcinomas with MET mutations display type 1 histology (Lubensky et al. 1999).  In 
addition, the MET region in chromosome 7q was excluded by linkage analysis on this 
locus with a logarithm of odds (LOD) score of < -2 (Launonen et al. 2001).  
Launonen et al. (2001) performed a genome wide linkage analysis in the two Finnish 
HLRCC families and succeeded in localizing the predisposing gene to chromosome 1q42-
q44 (Launonen et al. 2001). The telomeric region of the long arm of chromosome 1 was 
the only region showing suggestive evidence of linkage, and after an analysis with 
additional markers in the target region, the highest LOD score of 4.11 was achieved at 
microsatellite marker D1S2811. Additional evidence of the linkage in 1q42-q44 was 
obtained from the analysis of the third Finnish HLRCC family (Kiuru et al. 2001). 
LOH in tumors has been widely used as a predictor of location and function of tumor 
suppressor genes (Thiagalingam et al. 2002). Finnish researchers studied five renal cell 
cancers, three uterine leiomyomas, and seven cutaneos leiomyomas from HLRCC family 
members, and detected LOH at 1q42-q44 in all tumors except one renal cancer (Kiuru et 






chromosomal losses, 26 nonsyndromic uterine leiomyomas and 7 nonsyndromic 
cutaneous leiomyomas were analyzed for LOH in the HLRCC locus with informative 
microsatellite markers. Losses of the wild-type chromosome were detected only in one of 
these tumors, confirming that LOH seen in HLRCC lesion  is specific for the disease 
(Kiuru et al. 2001). According to linkage, haplotype, and LOH data, the HLRCC 
predisposing locus was mapped to an approximately 14 cM region between markers 
D1S517 and D1S404 (Kiuru et al. 2001). The localization of a tumor suppressor gene 
underlying the HLRCC syndrome in this region was strongly suggested.      
3.1.7. Multiple cutaneous and uterine leiomyomata ( MCUL) 
At the same time, but independently from the Finnish studies of the HLRCC locus, a 
genome-wide screen on 11 UK families with Multiple cutaneous and uterine leiomyomata 
(MCUL) found suggestive evidence of linkage (a maximum two-point parametric LOD 
score 1.84 at marker D1S157) to the q telomere of chromosome 1 (Alam et al. 2001). The 
families consisted of 54 affected individuals, most with multiple myomas of varying size. 
The initial genome screen detected a maximum LOD score of 1.84 at marker D1S547 in 
1q42.3-q43.8 regions with two-point analysis. With additional typing of microsatellite 
markers in this region, a multipoint LOD score of 5.4 was obtained between markers 
D1S2785 and D1S547/D1S404. After haplotype analysis, Alam et al. (2001) placed the 
predisposing gene for MCUL within a 14 cM interval between markers D1S517 and 
D1S2842. The loss of the wild type allele at the MCUL locus in two analyzed leiomyomas 
led UK researchers to argue that the predisposing ge e is a tumor suppressor.    
Evidence that the gene underlying MCUL syndrome is dominantly inherited with high 
penetrance was additionally provided. Of 33 females with the disease-associated 
haplotype, 29 (88%) had skin and/or uterine leiomyoas. Of 16 males with the disease 
haplotype, 13 had developed skin leiomyomata (Alam et al. 2001).    
 
4. Other familial cancers potentially associated to  
hereditary leiomyomatosis and renal cell cancer 
(HLRCC) 
4.1. Familial prostate cancer 
Hereditary prostate cancer (HPRCA) is a genetically complex disease involving multiple 
susceptibility genes and a strong environmental component. Segregation analyses in high-
risk prostate cancer families support a model of autosomal dominant inheritance with 
multiple rare high penetrance genes, particularly in early onset subgroups (Gronberg et al. 






chromosome 1q42.2-q43, named the putative predisposing gene for cancer of prostate 
(PCAP), spanning a 20 cM region (Berthon et al. 1998, Berry et al. 2000). The highest 
multipoint LOD score of 3.31 at the PCAP locus at marker D1S2785 was detected in the 
subset of early onset prostate cancer families (Berthon et al. 1998). LOH in prostate 
tumors at 1q42.2-43 further supported the linkage evidence and indicated that the causative 
gene may act as a tumor suppressor (Berthon et al. 1998). Linkage to the PCAP locus has 
remained unconfirmed in some data sets (Gibbs et al. 1999, Whittemore et al. 1999). 
These and other studies propose a heterogeneous background for HPRCA. Linkage 
analyses have indicated that several other chromosoal regions may be involved in 
inherited prostate cancer: a first putative hereditary prostate cancer locus (HPC1) at 1q24-
q25, prostate and brain cancer susceptibility locus (CAPB) at 1p36, hereditary prostate 
cancer X linked locus (HPCX) at Xq27-q28, hereditary prostate cancer locus at 
chromosome 20q13 (HPC20), and a putative prostate cancer gene HPC2/ELAC2 at 17p 
(Smith et al. 1996, Xu et al. 1998, Gibbs et al. 1999, Berry et al. 2000, Schleutker et al. 
2000, Tavtigian et al. 2001).  
A few genes have been reported to be mutated in HPRCA, none of them representing a 
high penetrance major susceptibility gene: ELAC2, ribonucleaseL (RNASEL) at the HPC1 
locus, 5  reductase type II gene (SRD5A2), and cytochrome P450c17 (CYP17) (Lunn et al. 
1999, Jaffe et al. 2000, Rokman et al. 2001, Xu et al. 2001, Carpten et al. 2002, Rennert et 
al. 2002, Rokman et al. 2002, Wang et al. 2002). 
4.2. Familial breast cancer 
The susceptibility genes for familial breast cancer are still largely unknown. The major 
known high-penetrance predisposition genes BRCA1 and BRCA2 account for a majority of 
families with multiple cases of early-onset breast cancer and ovarian cancer, but only a 
small fraction of familial breast cancer without these characteristics (Vahteristo et al. 
2001, Ford et al. 1998). Genetic linkage studies have suggested breast cancer loci on 
chromosomes 2q32, 6q25, 8p21, and 13q22 (Kainu et al. 2000, Huusko et al. 2004, Seitz 
et al. 1997, Zuppan et al. 1991). So far, the putative susceptibility genes in these regions 
have not been identified. 
The rationale for linking breast cancer to HLRCC is that three Finnish patients in two 
HLRCC families had been diagnosed with breast cancer (Kiuru et al. 2001, Launonen et 
al. 2001). The first breast cancer detected in an HLRCC patient displayed lobular 
histology, a histology which comprises only 15% of unselected breast carcinomas 







AIMS OF THE STUDY 
1. To localize and identify the gene predisposing to the HLRCC syndrome 
2. To investigate the role of the HLRCC predisposition gene in prostate and breast 
cancer 
3. To investigate the role of the HLRCC gene mutations in nonsyndromic tumor 
types associated with HLRCC 








MATERIALS AND METHODS 
1. Familial samples  
1.1. HLRCC/ MCUL Families (I) 
Three Finnish HLRCC families were included in the gene localization, identification and 
mutation detection study. The biggest Finnish family, FAM-1, included four individuals 
with early-onset RCC and 17 individuals with leiomyomas of the uterus and/or skin 
(Launonen et al. 2001). The second family, FAM-II, included two siblings diagnosed with 
renal cell carcinoma at the age of 32 and 26 and one individual with uterine leiomyomas at 
the age of 41 (Launonen et al. 2001). The third family included seven individuals with 
multiple cutaneous myomatosis, three individuals with uterine leiomyomatosis and one 
individual with renal cell cancer (Kiuru et al. 2001). Additionally, 39 UK families 
displaying a typical MCL phenotype with leiomyomata of the skin and uterus were 
included in the study through collaboration (Alam et al. 2001). DNA from 42 probands, 
from 22 families, including 85 affected individuals was used in fine-mapping of the 
predisposing gene. Informed consent was obtained from the patients. This study was 
approved by the authorized ethics review committee of the Joint Authority for the Hospital 
District of Helsinki and Uusimaa (HUS). 
 
1.2. Finnish prostate cancer families (II) 
Finnish prostate cancer family samples were available from University of Tampere 
through collaboration. The sample collection has been described previously by Schleutker 
et al. (2000). Altogether 70 blood samples for DNA isolation from the youngest affected 
subjects, whose samples were available, of each of t e 70 Finnish families were obtained 
for mutation analysis. At least one inclusion criterion had to be fulfilled: (1) prostate 
cancer in three generations, (2) three or more first degree relatives with prostate cancer, or 
(3) two subjects with prostate cancer diagnosed under the age of 60. The average age of 
diagnosis was 62.2 years (range 44-79) and the number of affected subjects per family was 
3.2 (range 2-6). Two of the patients had kidney cancer, but their leiomyoma status was 








1.3. US prostate cancer families (II)  
A total of 152 prostate cancer families including 522 genotyped men were previously 
ascertained through the Mayo Clinic radical prostatectomy database (Gibbs et al. 1999). 
The research protocol and informed consent forms were approved by the Mayo Clinic 
Institutional Review Board. Nineteen prostate cancer families for fumarase (FH) mutation 
screening were selected on the basis of positive linkage information over PCAP locus. 
Two individuals from each family were screened for FH mutations. The average age of 
onset in the families was 64.89 years (range 54.75-69.67 years) and the average number of 
affected subjects in each family was 3.36 (range 2-6). Within these 38 individuals, kidney 
cancer was observed in six different kindreds in nie subjects altogether. Four of these 
cases also had prostate cancer. The average age at diagnosis of the kidney cancer cases 
was 58.55 years.  
1.4. Breast cancer families (III) 
DNA samples extracted from blood from 85 breast cancers genes 1 or 2 (BRCA1 or 
BRCA2) mutation-negative breast cancer patients were included in this study. Samples 
were collected at the Helsinki University Central Hospital (Vehmanen et al. 1997, Eerola 
et al. 2000, Vahteristo et al. 2001a, Vahteristo et al. 2001b). 75 cases were selected based 
on family or personal history of renal cell cancer, sarcoma, uterine cancer (including 
uterine sarcoma), lobular breast cancer, prostate cancer, or multiple myeloma. 26 of these 
families had one such malignancy, 32 families had two, 12 families had three, and five 
families had four or more such cancers. In addition, 10 breast cancer patients not fulfilling 
the above-defined cancer history were included in this study because the experiments were 
performed on a 96-well plate format and space allowed inclusion of these samples. These 
10 patients had at least one first-degree relative aff cted with breast or other cancer, or 
were themselves affected with a second cancer. 
 
2. Control individuals (I, IV) 
To investigate the population frequency of a putative Finnish founder mutation (I) and an 
FH allele detected in the germline of a uterine leiomy a patient (IV) 448 and 134 blood 
samples from anonymous control individuals, respectiv ly, were obtained from the 
Finnish Red Cross, Helsinki. Over 150 population based control samples were used to 






3. Tumor samples  
3.1 Tumors from HLRCC family members (I) 
Tumors from HLRCC/MCL family members were analyzed for allelic loss in 1q42.3-q43. 
Paraffin-embedded tissue blocks, hematoxylin/eosin-stained slides, and pathologists’ gross 
reports were obtained for histopathological analyses from the Departments of Pathology at 
Oulu University Hospital, Helsinki University Central Hospital, and Turku University 
Hospital (Kiuru et al. 2001, Launonen et al. 2001). Tumors included seven renal cell 
carcinomas, seven uterine leiomyomas, seven cutaneous leiomyomas, and one uterine 
leiomyosarcoma. Additionally, these tumors were analyzed for LOH or somatic mutations 
in the FH gene.   
3.2. Nonsyndromic tumor samples (IV, V) 
In the study IV, 200 nonsyndromic tumors from 194 individuals with no known family 
history of cancer were studied for FH mutations. The study focusing on tumor types 
observed in HLRCC syndrome (IV) included 10 cutaneous leiomyomas, 41 uterine 
leiomyomas 52 renal cell carcinomas, 18 uterine leiomyosarcomas, 35 other sarcomas, 29 
prostate carcinomas, and 15 lobular breast carcinomas. The histological subtypes of renal 
cell cancers included 9 papillary type tumors, 40 clear cell carcinomas, and three other 
tumor types. Five of the renal cell carcinomas displayed the rare papillary type II histology 
associated with HLRCC. Sarcomas included 2 extra-uterine leiomyosarcomas, 9 
liposarcomas, 5 histiocytomas, 4 osteosarcomas, 2 chondrosarcomas, 1 fibrosarcoma, 1 
Edwing’s sarcoma, and 11 sarcomas of undefined histology.  
In the study V evaluating the role of FH in nonsyndromic uterine leiomyomas, 153 lesions 
from 46 individuals were first analyzed for allelic loss at the FH locus, and when 
displaying LOH, screened for FH mutations (V). 
To further evaluate the role of FH inactivation in nonsyndromic tumorigenesis (V) a series 
of 299 malignant tumors representing 10 different malignant tumor types were analyzed 
for FH mutations. Samples included 52 papillary thyroid carcinomas, 60 ovarian tumors, 
44 nonlobular breast carcinomas, 14 testicular carcinomas of germ cell origin, 34 lung 
carcinomas, 23 colorectal cancers, 15 cutaneous melanomas, 18 adrenal 







4. DNA and RNA extraction, purification, and cDNA 
synthesis (I, II, III, IV, V) 
DNA from blood samples, cell lines, and fresh-frozen patient tissue samples was extracted 
according to the nonenzymatic method of Lahiri and Nurnberger (1991). DNA extraction 
from paraffin-embedded tissue samples was performed using protocol described by 
Kannio et al. (1996). The product was purified using the NucleoSpin PCR purification kit 
(Macherey-Nagel, Duren, Germany). Total cellular RNA (tRNA) was extracted using the 
RNeasy kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer’s 
instructions. The extracted total RNA (tRNA) was used for cDNA synthesis in a reverse 
transcriptase polymerase chain reaction (RT-PCR) according to the standard protocol 
(Promega, Madison, WI, USA).  
 
5. Microsatellite marker analysis (I, IV, V) 
5.1. Fine-mapping at chromosome 1q 
To map more finely the gene for HLRCC/MCUL, we obtained DNA from 42 individuals, 
including 22 linkage informative families. In addition to microsatellite repeats from public 
databases, we identified 28 microsatellite repeats at he HLRCC locus to attempt to restrict 
the target region (Table 2). Repeats were identified by text and Basic Local Alignment 
Search Tool (BLAST http://www.ncbi.nlm.nih.gov/BLAST/) searches of the draft genome 
BAC clone sequences (Sanger Center Institute, 2001). Primers for PCR were designed 
using the Primer3 server (http://frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi) 
(Rozen and Skaletsky 2000). PCR amplicons were run on an Applied Biosystems PRISM 
377 DNA sequencer (Applied Biosystems, Foster City, CA, USA) and fragment sizes 
analyzed by the Genescan 3.1 and Genotyper 2.5.2 software (Applied Biosystems). The 
most likely haplotypes assuming a minimum number of ecombinations were manually 
constructed in the target region. 
5.2. Loss of heterozygosity (LOH) analysis (I, IV, V) 
LOH analysis with 40 microsatellite markers, 12 from the commercial set (ABI medium 
density Linkage Mapping Set-MD10 (Applied Biosystems)) and 28 novel repeats, was 
performed on the available tumors from the HLRCC families to narrow down the target 
region of the predisposing gene to HLRCC (I) (Table 2).   
To study LOH in nonsyndromic uterine leiomyomas (V), genomic sequence covering the 






(http://www.ensembl.org) was scanned for novel microsatellite repeats using the Tandem 
Repeats Finder software (Benson 1999). We identified two microsatellite repeats, flanking 
the FH locus. The markers FH-C and FH-T were located 2.8 Mb centromeric and 0.3 Mb 
telomeric respectively from the FH locus. Primers for PCR for the repeats were as 
follows: FH-C (centromeric) forward primer 5’-AGCAATGATGGTTTCTCTCTCA-3’; 
FH-C reverse primer 5’-CAGCACTAGCAGAATATGTGTAA-3’; FH-T (telomeric) 
forward primer 5’-CCTTACCATTGCTCCCAAGA-3’; FH-T reverse primer 5’-
ACCTTCATCCCTGTCCTGTG-3’. PCR amplicons were run on an Applied Biosystems 
PRISM 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA) and fragment 
sizes analyzed by the Genescan 3.1 and Genotyper 2.5.2 software (Applied Biosystems). 
LOH was visually estimated from ABI PRISM chromatographs. 
 
 
Table 2. Summary of the methods used in this study. 
1 Loss of heterozygosity 
2 Fluorescence in situ hybridization 
3 Denaturing high-performance liquid chromatograph 
4 Single-stranded conformational polymorphism 
 
Special Aims Method Reference 
Fine-mapping of a target 
region/regions and localization 
of candidate susceptibility genes 
Additional genotyping of linked   
families/additional families with 
microsatellite markers 
LOH1 in tumors 
 
Study I 
Identification of the 
susceptibility gene and causative 
mutations 
Mutation detection with sequencing 
FISH2 
LOH and somatic mutations in tumors 
 
Study I 
Evaluation of population 







Functional consequences of the 
detected mutations 
 
Enzyme activity assay Study I 
Evaluation of the role of the 
predisposing gene in other 
familial cancers 
 
Mutation detection with sequencing and 
DHPLC 





Evaluation of the role of the 
predisposing gene in sporadic 
tumorigenesis 
 
Mutation detection by sequencing and 
DHPLC 









6. Agarose gel electrophoresis (I, II, III, IV, V) 
Specificity and intensity of all PCRs were verified using gel electrophoresis. 4 µl of a PCR 
product was mixed with 2 µl of loading buffer (95% of formamide, 20 mM of EDTA, 
0.05% of xylene cyanol, and 0.05% of bromophenol blue). The mixture was run on a 2.5% 
SeaKem LE Agarose gel (Cambrex Bio Science Rocland Inc., Rockland, ME, USA) in 1 x 
TBE buffer at 150 V for approximately 30 min. The bands were visualized under ultra 
violet light with ethidium bromide. 
 
7. Identification of transcripts on 1q42-q43 (I) 
Sequences used in gene predictions were derived from the chromosome 1 physical map 
published by the Sanger Center Institute. The nucleid ac d identification program called 
NIX, provided by the UK Human Genome Mapping Project Resource Center (UK), was 
used to identify ESTs and known putative novel and predicted genes in the target region. 
NIX is a genome annotation package which runs multiple gene prediction and comparative 
sequence analyses programs simulataneously (Jones et al. 2002). Target sequences were 
analyzed on both directions in overlapping segments of 20-500 kb. Exon-intron structures 
of the candidate sequences were extracted from NIX results web pages and verified by 
Blast search. Additionally, the NCBI Entrez Genome Map Viewer 
(http://www.ncbi.nlm.nih.gov/entrez/) and Ensembl Human Genome Server were used to 
find known genes in the target region. Most of the pr dicted transcripts were verified by 
RT-PCR amplification of human total mRNA (RNeasy kit, Qiagen). 
 
8. Fluorescence in situ hybridization (FISH) (I) 
Due to non-mendelian inheritance detected in two UK families and observations that RCC 
exists only in the Finnish HLRCC families, fluorescn e in situ hybridization analysis 
(FISH) was carried out to detect putative large germline deletions or rearrangements at the 
HLRCC locus (Table 2). Metaphase spreads of lymphoblast cell lines from probands from 
two Finnish families and two UK families were prepared by standard protocols. BAC 
clones (from RP11-467120 to RP11-211A7 from the Sanger Center map) in the target 
region were fluorescently labaled with Fluoro Green, Fluoro Red, and Cy5sUTP by nick 
translation (Amersham Pharmacia Biotech, Piscataway, NJ, USA), and hybridized 
overnight to metaphase spreads under competitive conditi ns. Slides were counterstained 
with 4,6-diamidino-2-phenylindole. Images were displayed using a cooled charge-coupled 
camera (Photometrics, Huntington Beach, CA, USA) attached to Axioplan 2 Imaging 
Microscope and SmartCapture 2 software (Applied Imaging, San Jose, CA, USA). This 






9. Mutation detection  
9.1. Single-stranded conformational polymorphism (S SCP) (I) 
SSCP analysis was used to evaluate the Finnish population frequency of a putative Finnish 
FH founder mutation using DNA samples from 448 anonymous blood donors using MDE 
solution (FMC BioProducts) (Table 2). PCR products were run on 0.6xMDE gels, at 4W 
for 20 hours in 0.6xTBE running buffer. SSCP gels were silver-stained according to 
standard protocols.  
9.2. Denaturing high-performance liquid chromatogra ph (DHPLC) 
(II, III, IV, V) 
FH mutation screening by DHPLC was performed on 38 US familial prostate cancer 
patients from 19 prostate cancer families (II), 85 Finnish breast cancer patients from 85 
breast cancer families (III), 267 malignant tumors from 267 Finnish patients (V), and 5 
uterine leiomyomas from 5 unrelated individuals displaying LOH in their myomas at the 
FH locus (V) (Table 2). DHPLC was also used to examine the population frequency of a 
FH change detected in the germline of a patient with uterine leiomyosarcoma (IV). DNA 
from healthy 134 controls was included.  
All 10 FH exons and the flanking intronic sequences were amplified in 50 µl reaction 
volumes consisting of 50 ng genomic DNA, 0.7xPlatinum PCR Buffer (Invitrogen, 
Carlsbad, CA, USA), 200 µM of each dNTP (Finnzymes, Espoo, Finland), 0.3 µM of both 
primers, and 1.25 U of DNA polymerase Platinum Taq (Invitrogen), 0.60 U of Titanium 
Taq (Clontech, Palo Alto, CA, USA), and 0.60 U of AmpliTaq Gold (Applied 
Biosystems). The mixture of the three enzymes was used to obtain high fidelity, 
sensitivity, and specificity. The hot start PCR cycling conditions were as follows: 94°C for 
12 min, followed by 35 cycles of denaturing for 30 s, varying annealing temperatures for 
30 s, elongation at 72°C for 45 s, and final extension at 72°C for 10 min. The denaturing 
temperature was lowered from 94°C to 89°C after 10 cycles. Reactions were carried out in 
a PTC-200 Peltier Thermal Cycler (MJ Research). 
Samples from two subjects were pooled before they wre denatured at 95°C for three min 
and reannealed by reducing the temperature 0.5°C/30 s for 45 min. DHPLC heteroduplex 
analyses were performed using an automated HPLC instrumentation with an Agilent 2G 
experimental dsDNA 2.1x75 mm 3.5-micron column (Agilent Technologies, Palo Alto, 
CA, USA). Samples from pools displaying aberrant chromatographs were reanalyzed 
individually. 
The melting temperatures for each amplicon were obtained using the algorithm at the 
Stanford DHPLC Melt program web page (http://insertion.stanford.edu/melt1.html). The 






described by Xiao and Oefner (2001) and tested with known polymorphisms.  The 
analytical acetonitrile gradient was composed by mixing Helix BufferPak A for DHPLC 
and 55-75% B (Varian Analytical Instruments, Walnut Creek, CA, USA) at a flow rate of 
0.4 ml/min. Single-base substitutions and small insertions or deletions can be detected 
with DHPLC by different retention times of homo- and heteroduplex double-stranded 
PCR amplicons under partial denaturation. The sensitivity and specificity of DHPLC have 
been shown to vary between 94% and 100% when compared to direct sequencing (Xiao 
and Oefner 2001). 
9.3. DNA and cDNA sequencing (I, II, III, IV, V) 
To identify the predisposing gene, mutation screening of 6 known genes, regulator of G 
protein signaling 7 (RGS7), FH, kynurenine 3-monooxygenase (KMO), opsin 3 (OPN3), 
CHM-like (CHML), and exonuclease 1 (EXO1), and 41 other candidate sequences, 
including predicted genes and ESTs, was performed. Exons and the flanking intronic 
sequences were analyzed by genomic sequencing of gen mic DNA of probands from three 
Finnish and 39 UK families (I) (Table 2).  
Genomic sequencing was used in 70 Finnish prostate c ncer families (II), and in 14 
sporadic testicular tumors in a study of sporadic counterparts of tumor types observed in 
HLRCC (IV), Sequencing was used also for specifying and confirming the changes 
detected by DHPLC (II, III, IV, V).   
Sequencing was carried out in the sequencing core facility at the University of Helsinki, 
Haartman Institute (Helsinki, Finland). PCR mixtures and conditions were the same as in 
the DHPLC analysis (see section 8.2.). PCR products were purified using the NucleoSpin 
PCR purification kit (Matcherey-Nagel, Duren, Germany) according to the manufacturer’s 
instructions. Direct sequencing of the PCR products wa  performed using the BigDye3 
termination chemistry (Applied Biosystems) and an ABI 3100 Genetic Analyzer (Applied 
Biosystems) according to the manufacturer’s instructions, and the sequences were 
analyzed with the Sequencing Analysis 3.0 software (Applied Biosystems). 
Pheochromocytomas were screened by sequencing of cDNA, because only the 
corresponding RNA was available (IV). Primers for the 5' fragment of FH were 
CTCCCTCAGCACCATGTACC (forward) and CCACTTTTGCAGCAACCTTT 
(reverse); for 3' fragment CTTGGGCAGGAATTTAGTGG (forward) and 
GCAGTTTCCTTTCAAACTTATCC (reverse). PCR reactions were performed in a 50 µl 
reaction volume containing 200 ng cDNA, 1xPCR buffer (Applied Biosystems), 300 
µmol/L each dNTP (Finnzymes), 1.25 of µmol/L of both primers, and 2.5 U of 
AmpliTaqGOLD polymerase (Applied Biosystems). MgCl2 concentrations were 2.8 
mmol/L for the 5' fragment and 1.4 mmol/L for the 3' fragment. The following cycling 
conditions were used for the 5' fragment: 10 minutes at 95°C, followed by 40 cycles of 
denaturation at 95°C for 45 seconds, annealing at 56°C for 1 minute, and elongation at 






the 3' fragment were used despite the annealing temperature, which was decreased from 
60°C to 57°C at 0.5°C per cycle, and from 57°C to 56°C after ive cycles.  
The corresponding cDNA of leiomyoma P4M3 was analyzed to detect a splicing defect on 
the mRNA level (V). Primers for cDNA amplification were as follows: forward primer, 
TGGTATGGCAGACTGGATCA; reverse primer, CACCACGCAGTTTTCTGTA. PCR 
reactions and conditions were slightly different from those for pheochromocytoma 5' 
fragment amplification in MgCl2 concentration (4.2 mmol/L), annealing
 temperature 
(57°C), and number of denaturing/annealing/elongation cycles. In order to separate 
differentially-spliced mRNA variants, P4M3 and the corresponding normal sample were 
run on a 1% agarose standard low melting gel (Bio-Rad Laboratories, Herculer, CA, USA) 
at 100 V for 60 min (V). The separated bands were cut from the gel. PCR products were 
purified using the QIAquick PCR purification kit 250 (Qiagen) according to the 
manufacturer’s gel extraction protocol. The purified products were reamplified using the 
same protocol as in the original cDNA PCR to get sufficient amount of template for 
sequencing reactions. The sequencing protocol for cDNA was the same as that for 
genomic sequencing.  
 
10. Fumarate hydratase enzyme activity assay (I) 
In order to study the functional relevance of FH mutations, enzyme activity of FH was 
assayed in lymhoblastoid cell lines from affected in ividuals and spouse controls and in 
leiomyomata according to the protocol described by Hatch et al. (1978) (Table 2). The 
assay is based on coupling of malate production by FH to nicotinamide adenine 
dinucleotide (NADP+) reduction via the malic enzyme. The fumarase enzyme present in 
the cells/ tissue catalyzes the conversion of fumarate to malate. Reduction of NADP+ to 
NADPH occurs via the malic enzyme in the conversion of malate to pyruvate. The 
formation of NADPH is measured by absorbance detection. The assay starts with fumarate 
(final concentration 10 nM), lymphoblast sonicate, 25 mM HEPES-KOH pH 7.5, 0.27 nM 
NADP+, 4 mM MgCl2, 5 mM potassium phosphate, and 0.2 units/ml of purified malic 
enzyme (EC I.I.I.40, Sigma, St Louis, MO, USA).  These measurements were carried out in 
the laboratory of Dr. Simon Olpin (Sheffield Children’s Hospital, Sheffield, UK). 
 
11. Splice site prediction (III) 
The potential effect of intronic and silent changes to splicing was predicted by 









1. Fumarase (FH) is the predisposing gene in the 
hereditary leiomyomatosis and renal cell cancer 
(HLRCC) syndrome (I) 
Because of similarities detected in phenotypes and overlapping linkage regions, it was 
evident that HLRCC and MCUL might actually be one and the same syndrome. In order 
to further narrow down the target region of the HLRCC/MCUL predisposing gene, 
additional genotyping in three Finnish and 19 UK families was performed. In addition to 
microsatellite markers in public databases, we ident fi d 28 new polymorphic tandem 
repeats between markers D1S517 and D1S2842/D1S404, which was the minimal disease 
locus previously defined by Alam et al. (2001) and Launonen et al. (2001). Haplotype 
constructions pointed out critical recombinations i two large families, FAM-1 from 
Finland and family n:o 307 from the UK. The disease locus was placed on the 1.6 Mb 
region between clones BAC RP11-25B4 (centromeric border) and BAC RP11-553N16 
(telomeric border). The target area could not been further narrowed down by LOH 
analysis of tumors.  
The co-occurrence of leiomyomas and renal cell cancer i  three Finnish families and non-
mendelian inheritance in two UK families suggested he possibility of large germline 
deletions in the target region. Deletions of 2.4 Mband 1.9 Mb were detected in two UK 
families (207 and 713, respectively) but not in any of the Finnish families in FISH 
analyses. The data matched closely the minimal region defined in microsatellite mapping.  
In the minimal region, 6 known genes, 17 putative pr dicted new genes, and 42 ESTs 
were identified. Most of the predicted genes and ESTs (14 and 32, respectively) 
recognized had no homology to any known gene or protein. The known genes included 
RGS7, FH, KMO, OPN3, CHML and EXO1). The majority of the candidate sequences in 
the minimal region were analyzed for mutations, butp ative pathogenic changes were 
found only in fumarase (fumarate hydratase, FH) located in the BAC clones RP11-
409K12 and RP11-527D7 (Table 3). The FH gene encodes a mitochondrial FH protein 
which is a key enzyme in energy metabolism, catalyzing fumarate to malate in the Krebs 
cycle, i.e. the tricarboxylic acid cycle (TCAC) (Figure 2). The FH gene has been believed 
to additionally encode a shorter cytosolic form. The cytosolic isoform of FH is involved in 
the urea cycle and amino acid synthesis. 
FH consists of 10 protein-coding exons, spanning over 22 kb in the human genomic 
sequence. The first exon encodes the mitochondrial signal peptide (named exon 0) of 44 
amino acids, and the other nine the mature mitochondrial protein of 466 amino acids. The 
numbering of the exons, amino acid residues, and nucleotide positions presented in this 
study is based on the mature cytosolic isoform of FH (NM_000143.2) (Figure 3).  
 






Table 3. Fumarase (FH) mutations detected in this study in hereditary leiomyomatosis and renal    
cell cancer (HLRCC)/multiple cutaneous and uterine leiomyomata (MCUL) (Study I) and in 
nonsyndromic counterparts of tumor types observed in HLRCC (Studies IV and V). 
 
1  Hereditary leiomyomatosis and renal cell cancer 
2  Finnish origin 
3  Loss of heterozygosity 
4  Renal cell cancer 







Family or tissue Origin M utation Exon Study 
HLRCC1 (UK) Germline Whole gene delet ion 0-9 I 
HLRCC (UK) Germline Whole gene delet ion 0-9 I 
HLRCC (UK) Germline Gln4Stop 1 I 
Sarcoma of a limb, (FIN2) Somatic (+LOH3) Arg8Glu 1 IV 
HLRCC (UK) Germline 58delC 2 I 
RCC4, HLRCC FAM-2 (FIN) Somatic (2nd hit) 121delTG 2 I 
HLRCC (UK) Germline Arg58Stop 2 I 
HLRCC (UK) Germline Arg58Stop 2 I 
HLRCC (UK) Germline Arg58Stop 2 I 
HLRCC (UK) Germline Asn64Thr 2 I 
HLRCC (UK) Germline Asn64Thr 2 I 
HLRCC (UK) Germline Asn64Thr 2 I 
HLRCC (UK) Germline Asn64Thr 2 I 
HLRCC (UK) Germline Asn64Thr 2 I 
HLRCC (UK) Germline Asn64Thr 2 I 
HLRCC (UK) Germline Ala74Pro 2 I 
HLRCC (UK) Germline His137Arg 3 I 
HLRCC (UK) Germline Gln142Arg 3 I 
ULMS5 (FIN) Germline His153Arg 4 I 
HLRCC FAM-1 (FIN) Germline 541delAG 4 I 
HLRCC FAM-2 (FIN) Germline 541delAG 4 I 
Cutaneous leiomyoma (FIN) Germline 541delAG 4 IV 
HLRCC (UK) Germline Lys187Arg 4 I 
HLRCC (UK) Germline Lys187del 4 I 
HLRCC (UK) Germline Arg190His 4 I 
HLRCC (UK) Germline IVS4-15T>G 4 I 
Uterine leiomyoma (FIN) Somatic (+LOH) Ala196Thr 4 V 
Uterine leiomyoma (FIN) Somatic (+LOH) IVS4 + 3A>G 4 V 
HLRCC (UK) Germline Gly239Val 5 I 
ULMS (FIN) Somatic (2nd hit) Leu240Stop 5 IV 
RCC, HLRCC FAM-1 (FIN) Somatic (2nd hit) Met285Arg 6 I 
HLRCC FAM-3 (FIN) Germline Arg300Stop 6 I 
Cutaneous leiomyoma (FIN) Somatic (2nd hit) Arg300Stop 6 IV 


























Figure 2. Tricarboxylic acid cycle (TCAC) and tumorigenesis. TCAC is the final common route 
for the oxidation of amino acids, fatty acids, and carbohydrates. Dysfunction of two TCAC 
enzymes has been reported to be involved in human tumogenesis so far. Biallelic inactivation of 
fumarase (FH) has been observed in most of the tumors in hereditary leiomyomatosis and renal 
cell cancer (HLRCC). Defects in three of the four components of succinate dehydrogenase (SDH) 




FH mutations were found in 25 individuals, covering all three Finnish families and 19 out 
of 39 UK families (Table 4).  Sequence alterations were found in 7 out of 10 exons and 
included 10 protein truncating changes (nonsense and frameshift mutations), 2 large 
germline deletions, 12 single amino acid substitutions, and 1 whole gene deletion (Table 
3). The missense mutations were targeted in highly conserved amino acids and none of the 
changes were reported as known polymorphisms in public databases nor were found in 








Table 4. Fumarase (FH) mutation positive hereditary leiomyomatosis and renal cell cancer 
















of the uterus 
References   
(mutations detected) 
Finland 6 6 5 (12) 2 (4) Study I            
Lehtonen et al. (2005) 
UK 38 42 1 (1)  Study I                  
Alam et al. (2003)        
Alam et al. (2005) 
USA 52 56 18 (38)  Toro et al. (2003)            
















Martinez-Mir et al. 
(2003)                      
Chuang et al. (2005) 
Poland 1 1 1 (1)  Chan et al. (2005) 




Two of the Finnish families, FAM-1 and FAM-2, shared a deletion of 2 base pairs at 
nucleotide 543 (of the mature mitochondrial protein), six UK families carried the same 
missense change Asn64Thr, and three UK families shared the nonsense mutation 
Arg58Stop. Common ancestry was not known for any of the families sharing the same 
mutation. In the third Finnish family, FAM-3, a truncating mutation Arg300Stop was 
detected (Table 3).  
Biallelic inactivation of FH was observed in 28 out of 32 (88%) tumors studied. Allelic 
loss was detected in most cases, in 21 out of 25 leiomyomas and in 5 out of 7 papillary 
renal cell cancers. The remaining two renal cancers displayed somatic second hits, a 2 
base pair deletion at codon 41 and a missense change Met285Arg.  
To confirm the hypothesis that an absence or reduction of FH through biallelic 
inactivation is the cause of tumorigenesis in HLRCC/M UL, FH enzyme activity was 
measured. The FH enzyme activity assay showed a significant decrease of enzyme activity 
in tumor samples (range 198-438 pmol/mg/min) compared to control values (459-1104 
pmol/mg/min). Lower FH enzyme activity in individuals with missense mutations 























Figure 3. Structure of the fumarase (FH) gene and the known mutations in hereditary 
leiomyomatosis and renal cell cancer (HLRCC), nonsyndromic tumors, and fumarase deficiency 
(FHD). FH consists of 10 exons. Exon 0 is the mitochondrial signal peptide. Mutations in HLRCC 
and FHD overlap. No genotype-phenotype correlation has been detected in HLRCC. The 
numbering of the exons, amino acid residues, and nucleotide positions are based on the mature 
cytosolic isoform of FH (NM_000143.2). Figure updated from Kiuru and Launonen (2004). 
 
2. Fumarase (FH) in familial prostate cancer (II) 
The occurrence of prostate cancer in a FH mutation carrier in one HLRCC family and a 
frequent occurrence of kidney cancer (nine cases in 19 families) among US HPRCA 
families showing linkage to 1q42.2-43 supported thepossible role of FH defects in 
prostate cancer predisposition (Launonen et al. 2001). No germline mutations in the 
coding sequence or within the conserved splice site regions of FH was detected in the 
series of 108 prostate cancer patients from 89 families. One unique base pair substitution 
T>C was observed in the 3‘-untranslated region (UTR), nine base-pairs after the 
termination codon of the gene. A silent polymorphism 798G>A was observed in five 
samples in exon 7, and there was one heterozygous sub titution C>T 11 base-pairs 






























Exon 0 (signal peptide)
R58P K424R









3. Fumarase (FH) in familial breast cancer (III) 
In this study, 85 Finnish breast cancer cases for FH mutations were analyzed. The 
rationale of the work was occurrence of breast cancers ases in Finnish HLRCC patients 
carrying a germline FH mutation (Launonen et al. 2001). Mutation analysis revealed no 
disease-causing changes. Three previously detected polymorphisms (unpublished data) 
were found: 798 G>A (Pro266Pro) (two individuals, one heterozygous and one 
homozygous), IVS2+61T>A (one individual), and IVS3+32A>G (one individual). The 
changes were not predicted to have an effect on splicing tested in silico by the NetGene2 
program. Most (75 out of 85, 88%) of the studied cases were selected based on positive 
family or personal history for tumors seen in HLRCC. 
 
4. The role of fumarase (FH) in nonsyndromic 
tumorigenesis 
4.1. Fumarase (FH) mutations in tumor types observed in HLRCC 
(IV) 
To clarify the role of FH in nonsyndromic tumorigenesis, tumor types associated with 
HLRCC/MCUL were analyzed for FH mutations. The extended series of 200 tumors for 
FH mutation screening included 10 cutaneous leiomyomas, 41 uterine leiomyomas, 52 
renal cell carcinomas, 53 sarcomas, 29 prostate carcinomas, and 15 lobular breast 
carcinomas (Table 5).  
In the nonsyndromic tumors, the frequency of FH mutations was very low, with mutations 
detected only in 3 out of 200 (1.5%) lesions. In the leiomyosarcoma from patient LS10, a 
missense mutation His153Arg in exon 4 and a nonsense mutation Leu240Stop in exon 5 
were detected (Table 3). The His153Arg change was found also in the germline, 
suggesting the familial origin of the case. The change occurred in the evolutionarily 
conserved region of FH. The change was not reported as a known polymorphism nor was 
detected in a panel of 268 control chromosomes. Patient LS10 was first diagnosed with 
uterine leiomyomatosis, and despite two myomectomies, the malignant uterine 
leiomyosarcoma was detected two years later. The young age of onset (32 years) was 







Table 5. Nonsyndromic tumor types analyzed for fumarase (FH) defect and observed mutations. 
Somatic mutations detected jointly with germline changes are shown in parentheses. 
 
1 Hereditary leiomyomatosis and renal cell cancer 
2 Loss of heterozygosity 
3 Fumarase 















Other Findings Reference 
HLRCC1 associated tumors      
Uterine leiomyomas 41    Study IV 
 129   
5% LOH2 at FH3 
locus 
Barker et al. (2002) 
 153  2 
3.3% LOH at FH 
locus 
Study V 
 45 1   Barker et al. (2005) 
Cutaneous leiomyomas 10 1 (1)  Study IV 
Uterine leiomyosarcomas 18 1 (1)  Study IV 
 26   54% AI4 at 1q42 Barker et al. (2002) 
 67 1   
Ylisaukko-oja          
et al. (2006)  
 9    Barker et al. (2005) 
Other sarcomas 35  1  Study IV 
Renal cell cancer 52    Study IV 
Other tumors 44    Study IV 
 15    
Matyakhina              
et al. (2005) 
Non-HLRCC associated 
tumors 
299    Study V 






In the cutaneous leiomyoma from patient IL10, a 2 base pair deletion 541delAG in exon 4 
was detected, in addition to the tumor, in the germ line of the patient (Table 3). This 
mutation was found previously in two Finnish HLRCC families, nevertheless no common 
ancestry is known. The 541delAG was not present in the 448 Finnish healthy controls. 
Additionally, a somatic nonsense mutation Arg300Stop was found in exon 6. 
The only biallelic inactivation of FH purely at the somatic level was found in a soft-tissue 
sarcoma. The sequence change Arg8Glu in exon 1 targeted an amino acid conserved in 
yeast and Escherichia coli. The tumor displayed also a loss of the wild type FH allele. At 
the time of the diagnosis, the patient was 48 years old and had a metastasized soft-tissue 
sarcoma in her right lower limb. 
4.2. Fumarase (FH) in nonsyndromic uterine leiomyom as (V) 
4.2.1. LOH analysis 
LOH at the FH locus was analyzed by two polymorphic microsatellite markers in the set 
of 166 unselected uterine leiomyomas from 51 individuals. The markers were located on 
either side of the FH locus. 153 leiomyomas from 46 individuals were informative for at 
least one of the markers. The presence or absence of LOH was visually evaluated based on 
the different heights of the allele peaks. Allelic loss was observed in five myomas (5 of 
153, 3.3% of myomas), derived from five different patients (5 of 46, 11% of patients). One 
of these lesions was informative with both markers and showed LOH at both marker loci, 
whereas the other four were informative at one marker, two with the centromeric and two 
with the telomeric microsatellite repeat. 
4.2.2. Fumarase (FH) mutation screening 
Five leiomyomas showing LOH were subjected to FH mutation screening by DHPLC to 
detect the putative second alteration in the remaining allele. Two myomas, P32M1 and 
P4M3, showed aberrant chromatographs in exon 4. To confirm the finding and define the 
actual mutations, all five myomas were reanalyzed by sequencing of exon 4.  Three 
lesions were mutation-negative, and two displayed a FH mutation. The three myomas 
where a mutation in exon 4 was not found were sequenced for the rest of the coding 
sequence. The result of this analysis was also negativ , compatible with the results from 
the DHPLC analysis.   
Myoma P32M1 harbored a missense change Ala196Thr (586G>A) in exon 4 (Table 3 and 
5). The altered amino acid is completely conserved among species from humans to 
Escherichia coli. This change was not found in six other leiomyomas from patient P32. 
Allelic  imbalance was not present at the Ala196Thr mutation site, suggesting that the 






site change IVS4 + 3A>G, which is predicted to result in deletion of exon 4. Loss of the 
remaining wild type allele at the mutation site was also seen. The additional two myomas 
from patient P4 were mutation-negative in sequencing of exon 4. Genomic normal tissue 
DNA samples from these individuals were sequenced for all FH exons but no alterations 
were detected, confirming the somatic origin of the mutations and nonsyndromic nature of 
the cases.  
The predicted consequence of the splice site change, deletion of exon 4, was confirmed by 
cDNA amplification and sequencing. Histopathological evaluation of the FH mutation-
positive lesions confirmed that they were typical leiomyomas without any distinct features 
such as atypia (data not shown).    
4.3. Fumarase (FH) mutations in non-HLRCC associated sporadic 
tumors (V) 
In the FH mutation analysis of this large series of non-HLRCC associated, nonsyndromic 
(apparently sporadic) neoplasias, including 10 malignant tumor types, were successfully 
examined (success rate 94%), but no coding region mutations or splice site changes wre 
identified (Table 5). Probable polymorphisms detected were as follows: silent change 
798G>A (10 tumors), and three intronic alterations IVS2-21A>T (six tumors), IVS3 + 
32A>G (one tumor), and IVS2 + 61T>A (one tumor). The heterozygous substitution frm 
C to T 11 base-pairs upstream from the translation initiation codon was observed in one 
papillary thyroid carcinoma. The corresponding germline change was detected in a 
familial prostate cancer patient, and therefore seems to be an infrequent polymorphism 
(II).   







1. Localization and identification of the predispos ing 
gene for hereditary leiomyomatosis and renal cell c ancer 
(HLRCC) (I) 
In the genome wide linkage study of two Finnish families, Launonen et al. (2001) 
demonstrated that the susceptibility gene for HLRCC is likely located on chromosome 
1q42-q44. Independently in UK, linkage and haplotype analysis of 11 families segregating 
MCUL showed evidence for linkage to the same region on chromosome 1q42-q43 (Alam 
et al. 2001). LOH analysis in tumors from HLRCC family mebers at 1q42-q43 was 
compatible with the linkage data and confirmed the findings. Detection of wild-type allele 
deletions at 1q42-44 in most tumors of both Finnish kindreds studied also suggested that 
the underlying genetic defect is associated with a umor suppressor function (Kiuru et al. 
2001, Launonen et al. 2001).  
In this study, the predisposing gene for the HLRCC syndrome was localized and 
identified. The critical step in the gene identificat on effort was that the minimal target 
region could be narrowed down to 1.6 Mb by combining marker data from Finnish and 
UK families. FH was the only gene out of 6 known genes and over 50 t anscripts in the 
minimal target region carrying putative pathogenic changes (I).  
In this study, it was further confirmed that the tumors from HLRCC/MCUL family 
members followed the classical Knudson’s model of tumor suppressor inactivation 
(Knudson 1971). All seven papillary renal cell cancers and 21 out of 25 leiomyomas 
studied showed inactivation of the wild type allele, in most cases through allelic loss (I). 
This finding was further confirmed by an FH enzyme activity assay which showed a 
significant decrease of enzyme activity in tumor samples compared to control values. 
Lower FH enzyme activity in individuals with missense mutations compared to the 
individuals with whole gene deletion or truncation of the protein indicates susceptibility to 
a dominant-negative effect (I). This phenomenon is logical given the fact that the 
functioning enzyme is a homotetramer. In subsequent studies it has come evident that the 
FH enzyme activity assay provides comprehensive sensitivity and specificity in detecting 
pathogenic FH alterations (Alam et al. 2003, Wei et al. 2005).  
These data strongly suggested that FH is a predisposing gene for HLRCC/MCUL and acts 
as a tumor suppressor. 
1.1. Fumarase (FH) gene 
The human FH gene consists of 10 exons encoding 510 amino acids (F gure 3). The first 
exon (exon 0) encodes a mitochondrial localization signal peptide (Edwards and 






with 66% identity shared between the human and S. cervisiae FH proteins. The lyase 
domain of human FH includes the catalytic site of the protein (Figure 2). The superfamily 
signature peptide is conserved between proteins including FH, aspartase, adenylosuccinate 
lyase, arginosuccinate lyase, and -crystallin (Estevez et al. 2002).  
Mitochondrial FH is a key enzyme in energy metabolism, catalyzing fumarate to malate in 
the Krebs cycle, i.e. the tricarboxylic acid cycle (TCAC) (Figure 2) (Krebs and Johnson 
1937). TCAC is the final common metabolic pathway for the oxidation of amino acids, 
fatty acids and carbohydrates under aerobic conditions generating high-energy molecules, 
ATPs (Stryer 1995, Rustin et al. 1997). In addition to the mitochondrial peptide, a 
cytosolic isoform of FH also exists. The cytosolic isoform of FH is involved in the urea 
cycle and amino acid synthesis. In humans, two FH isoforms have been shown to be 
encoded by a single gene (Tolley and Craig 1975, Edwards nd Hopkinson 1979b). 
Studies in rat suggested that mitochondrial and cytosolic fumarases are synthesized from 
one species of mRNA by two alternative translational i itiation codons (Suzuki et al. 
1989, Tuboi et al. 1990, Suzuki et al. 1992). According to yeast studies, there is only oe
translation product (Stein et al. 1994). After signal peptide cleavage by mitochondrial 
matrix peptidase, a subset of FH will be recruited back to the cytosol (Sass et al. 2001). It 
was further shown in yeast that proper and rapid fol ing of the protein is the driving force 
for the recruitment of processed FH back to cytosol (Sass et al. 2003).   
1.2. Fumarase deficiency (FHD) 
Mutations in FH, in a homozygous or compound heterozygous form, were originally 
found in a metabolic disease FH deficiency (FHD, OMIM 136850) characterized by 
neurological impairment and encephalopathy (Zinn et al. 1986, Bourgeron et al. 1994, 
Deschauer et al. 2006). FH enzyme activity is absent or significantly reduced in all FHD 
patients’ tissues due to homozygous germline mutations of the gene, and these patients 
usually die at the age of few months (Rustin et al. 1997). Although the decrease in the 
enzyme activity in FHD patients is similar compared to the HLRCC tumors, no 
leiomyomata has been reported in FHD, definitely because of the very short life span of 
these patients. FH enzyme activities of heterozygous parents of FHD patients are typically 







2. Fumarase (FH) in hereditary leiomyomatosis and r enal 
cell cancer (HLRCC) (I) 
2.1. Clinical features  
Leiomyomas of the skin and uterus were the most prevalent lesions in the HLRCC 
families (I). In Finnish HLRCC families these tumors were found in 87% (26 out of 30) of 
individuals segregating germline mutations in FH. Nevertheless, occurrence of RCC was 
limited to the three Finnish HLRCC families with low penetrance (7 out of 30 Finnish 
patients; 23%), renal lesions were crucial in the caracterization of the syndrome in 
Finland. Even though the phenotypes are congruent in ma y respects, the considerably 
high frequency of renal cancers among Finns and absence among UK MCUL families 
could not be explained by different mutation spectrums (Figure 3). Much more data will 
be needed to determine if tumor spectrums vary between populations or if the differences 
are due to selection bias. Finnish HLRCC families were collected and primarily 
characterized by RCC, more precisely according to it’s papillary type II histology, 
whereas UK families were identified merely based on multiple skin and uterine 
leiomyomas. Currently 112 HLRCC families segregating FH mutations have been 
identified world-wide (Table 4) (I) (Alam et al. 2001, Kiuru et al. 2001, Launonen et al. 
2001, Alam et al. 2003, Martinez-Mir et al. 2003, Toro et al. 2003, Kiuru and Launonen 
2004, Alam et al. 2005, Chan et al. 2005, Chuang et al. 2005, Lehtonen et al. 2005, Wei et 
al. 2005). Although there is no population-based information of the prevalence of 
HLRCC, it has been estimated to be very low (Kiuru and Launonen 2004).   
The penetrance of cutaneous and/or uterine leiomyomas is high, up to nearly 100%, in all 
populations (I) (Toro et al. 2003, Alam et al. 2005, Chuang et al. 2005, Wei et al. 2005). 
In HLRCC patients, uterine leiomyomas cause more sev re symptoms than in the general 
population. HLRCC myomas are more numerous and larger, appear at younger age, and 
result more often in earlier hysterectomy than other myomas (Alam et al. 2005, Toro et al. 
2003). In the UK study of MCUL, 87% of women with uterine fibroids also had skin 
leiomyomas (Alam et al. 2005a, Alam et al. 2005b). Cutaneous leiomyomas are benign 
tumors composed of interlacing bundles of smooth muscle cells with centrally located 
blunt-ended nucleus. The size of most skin myomas of HLRCC patients varies between 2 
and 20 mm and they diverge greatly in appearance (Alam et al. 2005). Cutaneous 
leiomyomatosis in HLRCC typically has early onset, ranging from 10 to 47 years (Toro et 
al. 2003, Alam et al. 2005). Penetrance estimates for skin leiomyomas are 100% in men 
and 76% in women. The higher number of skin myomas in men than in women suggests a 
putative role of hormonal regulation in these lesion  (Alam et al. 2003). 
In addition to benign lesions, malignant RCC and ULMS are present in a subset of 
HLRCC families. Currently, 52 patients with RCC have been identified in 24 HLRCC 
families, originating predominantly from Finland and the US (24 out of 112 families, 
22%) (Table 4) (Launonen et al. 2001, Kiuru et al. 2001, Alam et al. 2003, Wei et al. 






suggested striking differences in renal cancer prevalence between Finland and the UK (I). 
Only one metastasized collecting duct carcinoma case diagnosed at age 16 years was 
reported in the UK compared to 12 RCC cases in Finland (Alam et al. 2003, Lehtonen et 
al. 2005) (I). The currently available data still supports the original finding that the 
prevalence of kidney cancer is higher in Finland anthe US than in other populations 
(Table 4). A key feature in these RCC tumors is their istopathology, which was crucial in 
identification of the syndrome (Launonen t al. 2001). HLRCC renal tumors typically 
display rare papillary type 2 histology, but altogether two collecting duct renal carcinomas 
have also been described (Launonen et al. 2001, Alam et al. 2003, Wei et al. 2005). The 
age of onset is low (median 40.5 years in Finland) and the progression of the disease is 
aggressive (Launonen et al. 2001, Toro et al. 2003, Lehtonen et al. 2005).  
ULMS is a rare malignant mesenchymal tumor. At present, four patients with 
leiomyosarcoma in two HLRCC families have been identifi d. Interestingly, 
leiomyosarcoma cases are restricted to the Finnish population (Kiuru et al. 2001, 
Launonen et al. 2001, Lehtonen et al. 2005). The age of diagnosis of ULMS has varied 
from 30 to 39 years, whereas in the general population they typically occur in old age 
(Kiuru et al. 2001, Launonen et al. 2001, Lehtonen et al. 2005).  
In order to study the cancer risk and mutation spectrum in Finnish HLRCC families, 
comprehensive and unbiased data has been obtained from 868 individuals included in the 
FH mutation-positive families (Lehtonen et al. 2005). The risk analysis provided 
statistically significant results with 6.5-fold increased risk for RCC and 71-fold increased 
risk in ULMS compared to the general population. More evidence for the crucial role of 
FH was obtained from LOH analysis of the tumor samples available from FH mutation 
carriers. Somatic inactivation was observed in 83% (10/12) of renal cell tumors and in 
100% (3/3) of uterine leiomyosarcomas (Lehtonen et al. 2005). The results further 
confirmed our original finding that malignant lesions, predominantly renal cell carcinoma 
and uterine leiomyosarcoma, are significant components of HLRCC tumor spectrum. 
Other tumor types have also been detected in HLRCC families: breast carcinoma, prostate 
cancer, hematological malignancies, leiomyosarcoma f the skin, bladder cancer, brain 
tumor, and angiolipomata of kidney (Launonen et al. 2001, Toro et al. 2003, Alam et al. 
2005, Wei et al. 2005). Lehtonen et al. (2005) provided evidence that other malignancies 
may also be promoted by loss of FH. All four breast and one bladder carcinomas studied 
displayed loss of the wild type allele at the FH locus.  
Recently, the massive macronodular adrenocortical disease (MMAD) has been added to 
the list of HLRCC phenotypes (Matyakhina et al. 2005). An inactivating FH mutation was 
found in a patient with atypical Cushing syndrome (CS, OMIM 219080) due to MMAD 
with adrenocorticotrophic hormone (ACTH)-independent a d bilateral hyperplasia of the 
adrenal glands. MMAD is a rare heterogenous disorder of unknown etiology associated 
with CS. ACTH-independent CS is caused by adrenocortical tumors or hyperplasias. CS 
may also be part of a complex including cutaneous and cardiac myxomas, spotty 
pigmentation of the skin, and hypertension (Teding van Berkhout et al. 1986, Teding van 






2.2. Germline mutations of fumarase (FH) in hereditary 
leiomyomatosis and renal cell cancer (HLRCC) 
In the predisposing gene identification study (I), FH mutations segregating in HLRCC 
families included whole gene deletions 8% (2/25), truncating mutations 40% (10/25), or 
substitutions and deletions 52% (13/25) of conserved amino acids (Table 3). This mutation 
data did not display any logical support for genotype-phenotype correlation. Although 
Finnish changes were protein truncating mutations ad could potentially lead to more 
severe symptoms (a 2 bp deletion and a nonsense mutation), no malignancies were 
detected in UK families with truncating changes including whole gene deletions, two 
different nonsense mutations, and a 1 bp deletion causing a frame shift (I). In these 
families mutations tended to occur towards the amino terminus of the gene and some 
clustering of mutations could be detected in exons 2 and 4. Mutations Arg58Stop and 
Asn64Thr were detected in three and six UK families, r pectively, indicating the location 
of a putative mutation hot spot. Additionally, five of the mutations were detected between 
codons 181 and 190, representing the third possible hot spot. Two of these changes were 
found in the Finnish HLRCC families. In none of these cases could the possibility of 
founder mutations be excluded because of lack of sufficient haplotype information (I).   
Mutation analyses of additional HLRCC families have offered more detailed information 
about FH mutations and their distribution (Figure 3) (Kiuru et al. 2001, Launonen et al. 
2001, Alam et al. 2003, Martinez-Mir et al. 2003, Toro et al. 2003, Chan et al. 2005, 
Chuang et al. 2005, Lehtonen et al. 2005, Wei et al. 2005). Single base pair substitutions 
(78%, 87/112) represent the great majority of the mutations reported in HLRCC families. 
Only 14% of the substitutions are nonsense changes creating a stop codon. FH missense 
mutations have been recently found to be clustered to fully conserved amino acids, 
functional substrate-binding sites, or in the sub-unit interaction regions (Alam et al. 2005). 
No apparent phenotypic differences can be detected between mutation types (Figure 3).  
FH mutations have been detected in totally over 90% of published HLRCC/MCUL 
families (112 out of 120) reflecting homogenous genetic background of this syndrome 
(Table 4). 
In FH, exons 4 and 6 seem to be mutation hot spots although mutations extend along the 
whole gene. Thirty-five percent of FH germline mutations are located in exon 4, and 
almost half of these in codon 190. The second most cmmon change Arg58Stop, 
originally found in the UK, has been reported also in HLRCC families from other 
populations (Figure 3) (Chuang et al. 2005, Wei et al. 2005). Increasingly accumulating 
evidence for the non-existence of genotype-phenotype association comes from the finding 
that both of these hot-spot mutations have been detected in families with and without RCC 
(Wei et al. 2005).  Due to lack of haplotypes of key individuals, it remains unsolved if 
some of these mutations represent either an actual hot spot or a founder mutation (Kiuru 
and Launonen 2004, Wei t al. 2005).  
The reduction of FH enzyme activity (50%) in parents of FHD patients is very similar than 
activity in the germline of heterozygous FH mutation carriers in HLRCC families 






HLRCC have not been reported previously in heterozyg us parents or siblings of FHD 
patients. After careful examination, one heterozygous parent of FHD patients was 
observed to have cutaneous leiomyomas (I). This family, previously described by Gellera 
(1990), segregates a different missense change in the same codon (190) as one of the UK 
MCUL families (Arg190Cys and Arg190His, respectively) (I). Other genotypic 
similarities, such as Arg190His mutations, have also been observed in both FHD and 
HLRCC, therefore the mutation spectrum seems to overlap (Figure 3) (Kiuru and 
Launonen 2004). In two other families where clinical examination of HLRCC-related 
neoplasias was executed, no signs of leiomyomatosis n r RCC was detected (Remes et al. 
2004, Deschauer et al. 2006). In the first family the clinical examinations of the father and 
mother of these patients were made at the ages of 36 and 33 years, and for the second 
family at 46 and 52 years. FH enzyme activity in their fibroblasts was close to the 
expected 50% of the normal value. Furthermore, Alam et al. (2003) reported an FHD 
family where neither of the heterozygous parents had developed HLRCC-associated 
lesions. This outcome is extremely confusing considering the almost complete penetrance 
of myomatosis and early onset of symptoms in HLRCC. The median age of diagnosis in 
HLRCC leiomyomas is 25 (skin) to 30 (uterine) years, nd 36 (Finnish population) to 44 
years (North American patients) in RCC. Although overlap in the mutation spectrum and 
clinical features of FHD and HLRCC families exists, genetic and molecular mechanisms 
behind observed discrepancies remains unknown. 
 
3. The role of fumarase (FH) in other familial canc ers 
3.1. Familial prostate cancer (II) 
It was hypothesized that FH defects may be associated not only with HLRCC, but also 
with prostate cancer predisposition. An FH mutation carrier in one HLRCC family had had 
prostate cancer. Kidney cancer cases were unexpectedly fr quent among US HPRCA 
families showing linkage to 1q42.2-q43. The fact that the genetic locus harboring FH had 
been associated with hereditary prostate cancer made FH an attractive positional candidate 
for a prostate cancer predisposition gene.  The combination of functional and linkage data 
indicates that mutations in FH might underlie HPRCA in a subset of families. An 
extensive effort to screen for FH defects in HPRCA was performed to test the hypothesis 
that FH mutations may predispose to prostate cancer. 
Analyses of 89 high-risk HPRCA families, of which 19 showed suggestive evidence of 
linkage to 1q42.2-q43, was performed for FH mutations. The absence of coding region or 
splice site aberrations in this data set strongly suggests that FH is not a predisposing gene 
for hereditary prostate cancer. These conclusions were strongly supported by negative 
results from FH mutation screening of 160 affected individuals from 77 UK prostate 






Neoplastic formation of the prostate could in many ways be linked to TCAC. The product 
of the FH gene acts as a key enzyme in mitochondrial energy metabolism in the citric acid 
cycle. In normal prostate cells, the oxidation of citrate is inhibited by aconitase, which 
leads to the accumulation of citrate. Transformation fr m citrate producing benign cells to 
citrate oxidizing malignant cells appears to be a key event in prostate carcinogenesis 
(Costello and Franklin 2000). Mitochondrial aconitase (m-aconitase, ACO-2) catalyzes the 
first step leading to the oxidation of citrate via TCAC. In malignant prostate cells, citrate 
production, a characteristic phenomenon of normal prostate epith lial cells, is shifted 
towards citrate oxidation which is activated by m-aconitase overexpression regulated by 
testosterone and prolactin (Costello and Franklin 2000). Reaction between m-aconitase 
and superoxide generates free hydroxyl radicals th t may enhance mitochondrial oxidative 
damage (Vasquez-Vivar et al. 2000). Citrate serves as an oxidizable intermediate in TCAC 
and as a precursor for lipogenesis, which is accelerated in malignant cells possibly owing 
to increased ATP production (Costello and Franklin 2000).  
3.2. Familial breast cancer (III) 
An indication of the contribution of FH to mammary gland tumors was that three Finnish 
patients with FH mutations in two HLRCC families had been diagnosed with breast 
cancer (Kiuru et al. 2001). The first breast cancer detected in an HLRCC patient displayed 
lobular histology, a histology which comprises 15% of unselected breast carcinomas 
(Launonen et al. 2001).  
So far, patients with breast cancer have only been d tected in the Finnish HLRCC 
families, in three FH mutation-positive females (Kiuru et al. 2001, Launonen et al. 2001). 
Interestingly, two of these patients had also been diagnosed with uterine leiomyosarcoma. 
Breast cancer being the most common cancer type in females, it is conceivable that these 
cases detected in the Finnish families are actually sporadic ones (Finnish Cancer Registry, 
http://www.cancerregistry.fi (2004)). In this study, FH germline mutations were examined 
in 85 Finnish patients with breast carcinoma, but no disease-causing mutations were 








4. Fumarase (FH) defects in nonsyndromic tumors 
4.1. FH mutations in tumor types associated with HLRCC (IV ) 
To further evaluate the role of FH in tumorigenesis we analyzed nonsyndromic tumors for 
FH inactivation. Sporadic lesions, restricted to the umor types associated with HLRCC, 
were analyzed for FH mutations (Table 5). In this study, only one case of a somatic loss-
of-function of FH (a missense mutation with LOH) was found in an unspecified soft-tissue 
sarcoma of a lower limb. Additionally, one out of 10 cutaneous leiomyomas displayed a 
mutation also in the germline. The 2-bp deletion 541delAG in exon 4 was earlier found in 
two Finnish HLRCC families, although no common ancestry was known for them (I). The 
somatic second hit Arg300Stop was also identified (Table 3). The same mutation was 
detected also in one Finnish HLRCC family (I), which ould be explained by this being a 
mutation hot-spot region. Robust conclusions cannot be drawn about frequency of 
nonsyndromic cutaneous leiomyomas with an FH defect. That even a single mutation 
positive case (1/10) was detected in a dataset this small was surprising. More data will be 
needed to determine the role of FH in cutaneous lesions.  
In one case of 18 unselected uterine leiomyosarcomas, a germline FH defect coupled with 
a nonsense somatic mutation was also identified. All three tumors displayed biallelic 
inactivation of FH by two mutation events, further confirming the biallelic inactivation 
model of FH tumorigenesis. Surprisingly, no FH mutations were found in 52 analyzed 
RCCs. Although five tumors had some histological resemblance to renal tumors from 
HLRCC patients, only two shared considerable similarity. Considering the specific 
histology of the HLRCC related RCC, this collection f nonsyndromic renal tumors was 
not probably optimal for the detection of FH alterations.  
Previously, four cases with ULMS segregating FH mutations in two Finnish HLRCC 
families have been identified (Table 4) (Launonen et al. 2001, Lehtonen et al. 2005). In 
addition to this effort (IV) in the population-based cohort of early onset nonsyndromic 
leiomyosarcomas an FH amino acid change was found in 1 out of 67 (1.5%) tumors 
(Table 5) (Ylisaukko-Oja et al. 2006). According to these studies, the prevalence of FH 
germline mutations in nonsyndromic ULMS in Finland is 2.4 % (2/85). FH mutations in 
nonsyndromic ULMS have been examined in four separate studies including altogether 
120 lesions but ULMS with FH defects have not been reported in any population other 
than Finns (Table 5) (Barker et al. 2002, Barker et al. 2005, Ylisaukko-Oja et al. 2006) 
(IV). Altogether, among Finnish FH mutation positive women, there are six cases of 
histologically verified ULMS, as well as two cases with leiomyomas with atypia (Kiuru et 
al. 2001, Launonen et al. 2001, Kiuru and Launonen 2004, Ylisaukko-Oja et al. 2006). 
Diagnoses of ULMS were at very young ages, 27 to 39 years, and with atypia at 27 and 36 
years. In the general population, ULMSs are rare and typically occur in old age. These 
findings seem to support the hypothesis that leiomyosarcomas belong to the tumor 






Although germline FH mutations in nonsyndromic ULMS are rare, the question about 
association of benign leiomyomas and malignant leiomyosarcomas has arisen. This is of 
interest considering the elevated risk of ULMS among FH mutation carriers in Finland 
(Lehtonen et al. 2005) Although previous cytogenetic studies have been unable to provide 
a link between nonsyndromic leiomyomas and leiomyosarcomas, recent microarray 
expression data has provided evidence that some leiomyosarcomas may arise from 
leiomyomas (Levy et al. 2000). A rare subset of leiomyomas with chromosome 1 
deletions was clustered together with leiomyosarcomas (Christacos et al. 2003).  
Allelic imbalance (AI) has been observed in a UK dataset in 54% of nonsyndromic 
leiomyosarcomas (Barker t al. 2002). Association of FH defects and AI at 1q42 cannot be 
directly drawn, because random chromosomal aberrations are common in ULMS 
(Packenham et al. 1997, Hu et al. 2001). Interestingly, no LOH or somatic mutations were 
found in the ULMS with a germline mutation in a population-based effort (Ylisaukko-Oja 
et al. 2006). Significantly reduced FH enzyme activity was supported the preassumption 
of the dominant negative effect and pathogenic nature of missense mutations. 
PCR fragments amplified in this study covered only the coding sequence and the flanking 
intronic sequences of FH. Untranslated 5’ and 3’ regions, distant regulatory regions, and 
most of the intronic sequences were not analyzed. Like all PCR-based mutation-detection 
technologies, our mutation analysis method was not capable of detecting large genomic 
deletions or insertions. Epigenetic alterations, which nclude DNA methylation and 
histone modification, are also undetectable by standard DHPLC or genomic sequencing. 
In many cancer cells, tumor suppressor genes, such as VHL and retinoblastoma (RB1), are 
inactivated by hypermethylation of their promoter CG-rich regions designated as CpG 
islands (Sakai et al. 1991, Herman et al. 1994). To examine possible epigenetic 
mechanisms in FH inactivation, Barker et al. (2005) used immunohistochemistry to study 
FH protein expression in nonsyndromic ULMS. No changes in FH expression was found 
in any of the 9 tumors studied.  
4.2. Fumarase (FH) in nonsyndromic uterine leiomyom as (V) 
It has been demonstrated that germline FH mutations predispose to myomas of the uterus 
and skin with high penetrance in HLRCC families (I). Biallelic inactivation of FH, in the 
majority of cases by LOH, is essential for FH related tumor growth. However, no FH 
mutations were found in our first set of 26 unselected nonsyndromic uterine leiomyomas, 
based on the previous findings somatic FH mutations do occur, though at a low frequency 
(I, IV). It was hypothesized that if FH is associated with the development of nonsyndromic 
uterine leiomyomas, most mutations should be found in lesions displaying allelic loss at 
1q43. To test this hypothesis an extensive set of nonsyndromic 166 uterine myomas was 
analyzed, first for LOH at the FH locus, and in the presence of allelic loss additionally for 






In this study, allelic loss at the FH locus was detected in five of 153 (3.3%) informative 
unselected leiomyomas from 46 individuals (10.9%). Somatic FH mutations were detected 
in two out of five cases displaying LOH in the region of the FH locus. The wild type A 
allele seems to be under-represented in the sequence chromatograph of the IVS4 +3 A>G 
mutation site. This finding together with the LOH data supports our conclusion that FH is 
inactivated through a somatic point mutation and loss f the second allele, and is a true 
target of the 1q43 deletions.  
A negative germline FH mutation analysis of all exons, performed from normal tissue 
DNA, confirmed the nonsyndromic nature of both of the mutation-positive lesions and 
excluded the possibility of polymorphism. The FH mutation data obtained are quite 
convincing. The missense mutation affects a conserved amino acid, and changes the amino 
acid subclass from neutral and hydrophobic to neutral and polar. The splice site change 
results in deletion of the entire exon 4. Both mutations are located in the FH mutation hot 
spot detected in HLRCC families (Figure 3). Three lesions displayed LOH at the FH locus 
but no mutations were detected. Although random allelic loss is rare in uterine 
leiomyomas (Mao et al. 1999), random deletion of a chromosomal material at 1q cannot 
be excluded in the three mutation-negative cases. To determine the frequency of loss of 
FH in uterine myomas, Gross et al. (2004) performed a FISH analysis of 11 tumors with 
1q rearrangements. Their data, showing absence of one copy of FH in nine of 11 myomas, 
suggested that loss of FH is involved in the development of a subset of nonsyndromic 
uterine leiomyomas. Furthermore, mosaicism in these tumors indicated that chromosome 
1 cytogenetic rearrangements are secondary changes in the pathogenesis of nonsyndromic 
uterine leiomyomas. Multiple reports of cytogenetic rearrangements, alterations in gene 
expression, and analysis of candidate genes in uterine leiomyomas have been published in 
the last few decades, reviewed by Newbold et al. (2000). Barker et al. (2005) studied FH 
expression in a series of nonsyndromic 45 uterine leiomyomas, but found no evidence of 
contribution of epigenetic mechanisms to formation of these lesions.  
Our LOH derived study design was based on the existing knowledge that in most of the 
hereditary cases, biallelic inactivation of FH results from loss of a wild type allele. We 
have found point mutations in a very small number of tumors. In other studies examining 
FH mutations on unselected sets of uterine leiomyomas, only one germline mutation was 
detected with loss of the normal allele (Barker et al. 2002, Barker et al. 2005). Altogether 
368 nonsyndromic uterine leiomyomas have been studied for FH alterations, but only 
three mutations have been detected (1 germline and 2 somatic) (Table 5).  
This is the first time, to our knowledge, that specific inactivating point mutations in 
nonsyndromic uterine leiomyomas have been detected in any gene. Although mutational 
FH inactivation in nonsyndromic uterine leiomyomas is uncommon at the tumor level, the 
frequent co-existence of multiple myomas in patients suggests that the occurrence of FH-
deficient leiomyomas is not extremely rare. Overall,  minimum of 2.8% (2 of 72) of our 
Finnish uterine nonsyndromic leiomyoma patients harbored FH somatic mutations in at 
least one of their myomas. This study further confirmed the hypothesis that FH acts as a 






To investigate the role of FH in sporadic tumorigenesis, 652 lesions, including a series of 
353 nonsyndromic counterparts of tumor types associated with HLRCC, were analyzed 
(IV, V) (Table 5). In this study, altogether five of the tumors displayed biallelic 
inactivation of FH, three out of them purely on a somatic level. FH mutations in 
nonsyndromic tumors are rare (5 of all 652 lesions, 0.8%) and appear to be limited to the 
counterparts of tumor types associated with HLRCC (5 out of 353 HLRCC-associated 
tumor types, 1.5%). Word-wide, seven tumors with an FH mutation have been detected in 
studies including 644 HLRCC associated nonsyndromic lesions (1.1%) (Table 5).  
 
5. Function of tricarboxylic acid cycle (TCAC) gene s in 
tumor predisposition 
5.1. Function of fumarase (FH) mutations  
The recent findings that FH, known as a housekeeping–like gene, acts as a predisposing 
gene in cancer has encouraged efforts to better understand molecular alterations promoted 
by TCAC defects. Considering the logical correlation of observed FH enzyme activity and 
tumor predisposition in HLRCC-related tumors, it could be postulated that the effect is 
mediated through the function of the enzymatically ctive homotetramer (I).  
Evidence that FH defects are mediated through TCAC was given by Kokko et al. (2005) 
who studied the effect of HLRCC-associated FH missense mutation and knock-out strains 
in yeast using a microarray platform. Two previously identified putative pathogenic 
mutations were analyzed: His153Arg associated with malignant phenotype (RCC and 
ULMS) and Lys187Arg associated only benign myomas and FHD (Coughlin et al. 1998) 
(I). Generally, transcription of the majority of TCA enzymes was down-regulated in 
response to FH mutations (Kokko et al. 2005). Differences between the mutants could not 
be detected in FH expression, FH enzyme activity or in regulation of genes responding to 
FH mutations. Additionally, FH knock-out strains showed, in general, expression patterns 
similar to mutants. According to these findings, modifier gene/genes rather than genotype-
phenotype correlation could better explain the heterog neity in symptoms seen in families 
segregating different FH mutations.  
To examine a poorly understood mechanism leading from FH defects to neoplastic 
pathway in uterine leiomyomas Vanharanta et al. (2005) used a genome wide expression 
microarray approach for showing differences in gene xpression in FH-deficient compared 
to proficient uterine leiomyomas. Both nonsyndromic FH mutation-positive myomas, 
4M3 and 32M1 (IV), and 7 familial myomas from a patien  from a Finnish HLRCC family 
(I), were compared to 15 fibroids with wild type FH. All studied myomas, except two 
from the familial individual, showed LOH at the FH locus reflecting biallelic inactivation 
of the gene. Among 297 differentially expressed genes, the most interesting up-regulated 






which has been activated in many malignant tumors and ssociated with invasive 
phenomena (Gatenby and Gillies 2004, Vanharanta et l. 2005). Additionally, genes 
related to apoptosis (apoptois-antagonizing factor, AATF, CDKN1A), cell cycle arrest 
prevention (transketolase, TK), muscle development, and call adhesion were shown t  be 
differentially expressed (Rais et al. 1999, Kogel et al. 2001, Di Padova et al. 2003, 
Vanharanta et al. 2005). FH mutant myomas also showed increased expression of iron 
homeostasis and oxidoreduction genes, possibly due to oxidative stress. Generally, 
published expression data indicated that FH inactivtion-derived tumorigenesis is more 
likely to be related, directly or indirectly, to the pathways linked to TCAC than to other 
possible, currently unknown, functions of FH.  
5.2. Succinate dehydrogenase (SDH) genes in tumorig enesis  
FH mutations found in HLRCC made it evident that dysfunction of TCAC plays a general 
role in tumorigenesis. Just prior to definition of the HLRCC syndrome, the observation 
that a TCAC component could be involved in tumorigenesis was made by Baysal et al. 
(2000). Germline mutations in subunits of succinate-ubiquinone oxidoreductase, succinate 
dehydrogenase subunit D (SDHD), were observed in patients with hereditary head an  
neck paraganglioma (HPGL) and pheochromocytoma, and somatic mutations were 
detected in respective nonsyndromic lesions (Baysal et al. 2000, Gimm et al. 2000, Astuti 
et al. 2001a, Astuti et al. 2001b, Baysal et al. 2001, Baysal et al. 2002). Subsequently, it 
was suggested that germline SDHB mutations can predispose to early-onset kidney 
cancers, showing some similarities in the tumor spectra of FH and SDH mutations 
(Vanharanta et al. 2004).  
Paraganglioma and pheochromocytoma are tumors of the autonomic nervous system. The 
term paraganglioma is used for benign extra-adrenal tumors typically located in the head 
and neck area, whereas pheochromocytomas are define according to their adrenal 
medulla origin (Maher and Eng 2002). The four succinate dehydrogenase subunits, 
SDHA, SDHB, SDHC, and SDHD, comprise mitochondrial complex II of the electron 
transport chain and catalyze the oxidation of succinate to fumarate (Figure 3). In the 
TCAC, fumarate is converted to malate by FH. Although the tumor spectrum in HLRCC 
and PLG is different, it has been postulated that mu ations in FH and SDH genes affect 
same molecular pathways (Gottlieb and Tomlinson 2005). This hypothesis is supported by 
a yeast study where defects in either SDH or FH had been shown to produce similar 
expression patterns (McCammon et al. 2003). Similarly to FH alterations in nonsyndromic 
uterine leiomyomas, allelic loss and somatic mutations n SDHB and SDHD have been 






5.3. TCAC defects and apoptosis  
Several explanations have been given concerning mechanisms of tumorigenesis caused by 
mutations in FH, including apoptosis and mitochondrial dysfunction, xidative stress, 
pseudo-hypoxia, anabolic drive, or unknown function of the cytosolic form of FH (Eng et 
al. 2003, Pollard et al. 2003, Kiuru and Launonen 2004, Gottlieb and Tomlinson 2005). 
Mitochondria have a central role in programmed cell death. In response to upstream 
signals apoptotic proteins such as cytochrome c are released from the mitochondria and 
activate the energy-dependent apoptotic protease cascade (Liu et al. 1996, Li et al. 1997, 
Earnshaw 1999). The role of SDHC as an apoptotic regulator has been proposed in a 
number of studies (Albayrak et al. 2003, Ishii et al. 2005).  
5.4. TCAC defects and reactive oxygen species (ROS)  
Defects in mitochondrial metabolism have been suggested to promote production of 
reactive oxygen species (ROS) (Arosio and Levi 2002, Rustin 2002). ROS have been 
proposed to participate in the etiology of cancer and ging (Oberley and Buettner 1979, 
Oberley 2002). Overproduction of ROS and changes in cellular energy metabolism had 
been previously detected in ceSDHC (homologous to human SDHB) mutant in 
Caeornorhabditis elegans (Ishii et al. 1998, Senoo-Matsuda et al. 2001). Ishii et al. (2005) 
tested this phenomenon in mammals using a transgenic c ll line with a mutated SDHC 
gene and detected over-produced superoxide anion (one type of ROS), elevated apoptotic 
rate, and significantly higher mutation frequency compared to wild type constructs. In 
contrast to this finding, two other studies observed n ither ROS generation or nor a shift to 
a more oxidized state in SDH- and FH-deficient celllines (Pollard et al. 2005, Selak et al. 
2005).  
5.5. Pseudo-hypoxia model of mitochondrial tumor su ppression 
Most evidence has been obtained for the pseudo-hypoxia model derived by loss-of-
function of mitochondrial tumor suppressor genes. Recently, evidence has been presented 
that HPLG tumors have activated hypoxia and angiogenic pathways, i.e. vascularization 
(Gimenez-Roqueplo et al. 2001). Pheocromocytomas are also associated with VHL, which 
is the most common condition predisposing to hereditary RCC (Maddock et al. 1996). 
Pheochromocytomas with VHL, SDHB, or SDHD mutations have been linked together by 
HIF1α mediated hypoxia pathway signals (Dahia et al. 2005). The existence of an 
autoregulatory loop where HIF1α contributes to decreased SDHB levels, resulting in 
mitochondrial complex II inhibition, was supported. Mutations in the VHL gene cause 
stabilization of the sub-units of hypoxia-inducible factors (HIF) resulting in activation of 
pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) (Maxwell et 






regulation of VEGF and BCL2 interacting protein 3 (BNIP3), and down-regulation of 
thrombospondin 1 (TSP1) were found in HLRCC uterine leiomyomas. The VEGF 
promoter contains a hypoxia response element and the protein is an angiogenic activator 
through induction of cell proliferation and inhibition of apoptosis (Leung et al. 1989). 
Contrary to VEGF, TSP1 suppresses angiogenesis by inducing endothelial cell apoptosis 
(Nor et al. 2000).    
It has been previously suggested that succinate, the TCAC intermediate and respiratory 
chain substrate, is capable of restoring the HIF1α hypoxic induction through electron 
transport chain or through some metabolic pathway (Agani et al. 2000, Agani et al. 2002). 
Using the RNAi technique Selak et al. (2005) described a mitochondria-to-cytosol 
signaling pathway that links mitochondrial defects to tumorigenic processes. Down-
regulation of SDH activity caused accumulation of succinate in mitochondria. Succinate is 
freely transported to cytosol where it is able to inhibit HIF1α prolyl hydroxylases (PHD), 
















Figure 4. Molecular effects of TCAC blockage in FH/SDH deficient tumors. Inactivation of FH 
results in accumulation of fumarate and succinate in mitochondria. The excess amount of these 
enzymes will be transported to cytosol. Elevated fumarate and succinate inhibit thereby HIF1α 
hydroxylation leading to decreased binding of pVHL to HIF1α. Increased HIF1α activity results in 
changes in hypoxia pathway (upregulation of VEGF, BNIP3, and GLUT1, and down-regulation of 
TSP1). IN SDH deficient tumors, signaling is driven predominantly through accumulation of 



























This event stabilizes HIF1α and leads to activation of the HIF pathway in kidney cells.  
Pollard et al. (2005) confirmed these findings in benign and malignant HLRCC tumors. 
HIF1α over-expression, moderate in HLRCC myomas and strong in HLRCC clear cell 
cancer, probably due to accumulation of fumarate and succinate, was demonstrated. 
Accumulation of succinate and over-expression of HIF1α and VEGF was shown also in 
SDHB-deficient HPGL tumors.  
HIF1α and HIF2α over-expression was observed directly in renal tumor tissues from 
HLRCC patients by Isaac et al. (2005). To test the hypothesis that the HIF over-
expression is due to loss of FH, conditions in HLRCC tumors were mimicked in cells 
using FH/SDH inhibitor, 3-nitropropionic acid (3-NPA). Accumulation of fumarate due to 
FH inhibition correlated with HIF upregulation in protein but not in the mRNA level. 
Isaac et al. (2005) further demonstrated that an increase in the intracellular fumarate level 
up-regulates VEGF and GLUT1 in a HIF-dependent manner.  
VEGF is a key mediator of angiogenesis in the majority of human tumors, because it 
facilitates endothelial cell proliferation, promotes cell migration, and inhibits apoptosis 
(Leung et al. 1989, Neufeld et al. 1999, Bergers and Benjamin 2003). VEGF expression i  
induced by a large number of growth factors, hypoxia, or acidosis (Shweiki et al. 1992, 
Fukumura et al. 2001, Ferrara 2004). VEGF over-expression has been d monstrated in 
fumarate-induced cells and in HLRCC myomas (Isaacs et al. 2005, Pollard et al. 2005). 
Microvessel density, probably due to response to hypoxia, has been shown to be 
remarkably higher in HLRCC leiomyomas compared to surrounding myometrium or 
sporadic, FH proficient myomas (Pollard et al. 2005). However, it remains unknown how 
activation of angiogenic signaling leads to tumor growth through accelerated cell 
proliferation or decreased cell death.  
Most human invasive cancers show significant increases in glucose uptake because of 
upregulation of glucose transporters, notably GLUT1 and GLUT3, and hexokinases 
(Mathupala et al. 1997, Macheda et al. 2005). Glygolysis requires conversion of glucose 
to pyruvate and then to lactic acid. In normal human cells, glygolysis is inhibited by 
oxygen leading to oxidation of pyruvate in mitochondria. Increased glycolysis in the 
presence of oxygen and accumulation of lactate are well known phenomenon of cancers, 
leading to microenvironmental acidosis (Weinhouse 1976). Main intracellular signals that 
lead to inappropriate activation of angiogenic pathways in TCAC-defective tumors are 
summarized in Figure 4. 
Hypoxia and energy starvation have been shown to activate multiple key regulators, such 
as translation eukaryotic initiation factor-2-alpha (eIF2α), eukaryotic elongation factor 2 
(eEF2), and mTOR effectors eukaryotic initiation factor 4E (eIF4E) binding protein 1 
(4EBP1) and p70S6K  kinase, independent of HIF (Liu et al. 2006). These effects could be 
potentially linked to FH mutation-derived tumorigenesis through altered energy 






Mitochondrial involvement in common multifactorial cancers could be also speculated. 
Significant decreases in the activities of mitochondrial enzymes, including ketoglutarate 
dehydrogenase (KDH), malate dehydrogenase (MDH), and SDH was detected in 
benzo(a)pyrene-induced lung tumors in mice (Selvendira  et al. 2005). 
In conclusion, the molecular mechanisms of FH derived tumorigenesis require more 
detailed examination. Most evidence has been obtained for the pseudo-hypoxia model of 
mitochondrial tumor suppressor function. Similarities in clinical symptoms and molecular 
background between the tumor predisposition syndromes link defects in FH, SDH, VHL, 
and TSC1/2 to overlapping pathways, probably through HIF signaling.   
  
 
6. Clinical implications 
The accurate diagnosis of HLRCC has become possible w th the identification of the FH 
gene mutations causing the syndrome. The recognition of mutation carriers is particularly 
important because these persons are at risk of developing malignant cancers, especially 
RCC and ULMS. The renal cancers which are related to the HLRCC syndrome seem to be 
exceptionally aggressive, and the majority of these patients die because of metastasized 
disease shortly after diagnosis (Launonen et al. 2001). Consequently, regular follow-up of 
the mutation-positive family members is important. On the other hand, the unnecessary 
follow-up of mutation-negative members of the family can also be avoided. Due to the 
aggressiveness of renal lesions in HLRCC, in contrast to other hereditary renal cancer 
syndromes, immediate radical hysterectomy has been r commended for HLRCC patients 
with renal tumors (Kiuru et al. 2004).  
In Finland, genetic testing is very well accepted an the subjects have been satisfied with 
their decision to take tests (Liljestrom et al. 2005). Neither increased anxiety nor other 
long-term psychological consequences have been detected regarding genetic testing when 
combined with proper genetic counseling and support among HNPCC patients (Aktan-
Collan et al. 2001). Therefore, genetic testing of FH mutations should be considered also 
among HLRCC family members. 
Discovery of TCAC defects in human tumor predispositi n increases our knowledge of 
molecular mechanisms of tumorigenesis in general. Further insight into the role of basic 
cellular energy metabolism may help us to better understand complex genetic and 
environmental interactions in common tumors, like ut rine leiomyomas. Differences in 
mitochondrial function between normal and cancer cells might offer potential for 






CONCLUSIONS AND FUTURE PLANS 
1. This study describes a novel cancer gene. Fumarase (FH) mutations predispose, with 
high penetrance, to dominantly inherited cancer syndrome, HLRCC/MCUL. Biallelic 
inactivation of FH, in the most cases through LOH, is typically needed for tumor 
development, suggesting the role of FH as a tumor suppressor.  
2. FH is unlikely to be a predisposing gene in other studied familial cancers, breast and 
prostate cancers.  
3-4. Data from nonsyndromic tumor studies, including 943 lesions, show that mutations in 
FH are rare outside the HLRCC context. Purely somatic biallelic inactivation of FH has 
been detected in this study only in two uterine leiomyomas and one soft-tissue sarcoma. 
Additionally, we have found somatic mutations combined with inherited FH alterations in 
one cutaneous leiomyoma and one uterine leiomyosarcma. In addition to this study, only 
two FH mutations in nonsyndromic tumors, one uterine leiomy ma and one 
leiomyosarcoma, both with germline changes, have been found. Studies in apparently 
sporadic tumors have given further evidence to the proposed Knudson’s two-hit model of 
FH inactivation. This study also shows additional evid nce that uterine leiomyosarcoma 
belongs to the tumor spectrum of HLRCC. 
FH mutations appear to be rare in nonsyndromic tumors, and when they exist, seem to be 
restricted to tumor types associated with the HLRCC syndrome. However, our strategy of 
using LOH as a preliminary target indicator identifies FH as the first gene known to 
undergo somatic inactivation in nonsyndromic uterine leiomyomas by specific point 
mutations. This is of great clinical interest, because leiomyomas are the most common 
tumors of women. To our knowledge, FH is the first gene shown to undergo mutational 
inactivation, in both the somatic and hereditary forms of the disease, in leiomyomata of 
the uterus.  
Much effort will be needed to define the actual molecular mechanism of how FH 
inactivation leads to accelerated tumor growth, andwhich factors determine phenotype 
differences in FH mutation carriers and differences in frequencies of malignant tumors in 
different populations. We believe that a combinatori l effect of FH and an unknown 
modifying gene is needed for predisposition for ULMS and RCC in HLRCC. One of our 
current main efforts, in addition to FH related functional studies, is to localize and identify 
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